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ABSTRACT

STATISTICAL ANALYSIS AND DATA MINING OF MEDICARE PATIENTS
WITH DIABETES

Xiao Wang
March 25, 2011
The purpose of this dissertation is to find ways to decrease Medicare costs and to
study health outcomes of diabetes patients as well as to investigate the influence of
Medicare, part D since its introduction in 2006 using the CMS CCW ( Chronic
Condition Data Warehouse) Data and the MEPS (Medical Expenditure Panel Survey)
data.
In this dissertation, we introduce pattern recognition analysis into the study of
medical characteristics and demographic characteristics of the inpatients who have a
higher readmission risk. We also broaden the cost-effectiveness analysis by including
medical resources usage when investigating the effects of Medicare, part D. In addition,
we apply several statistical linear models such as the generalized linear model and data
mining techniques such as the neural network model to study the costs and outcomes of
both inpatients and outpatients with diabetes in Medicare. Moreover, some descriptive
statistics such as kernel density estimation and survival analysis are also employed.
One important conclusion from these analyses is that only diseases and procedures, rather
than age are key factors to inpatients' mortality rate. Another important discovery is that
IV

at the influence of Medicare part 0, insulin is the most efficient oral anti-diabetes drug
treatment and that the drug usage in 2006 is not as stable as that in 2005. We also find
that the patients who are discharged to home or hospice are more likely to re-enter the
hospital after discharge within 30 days. Two - way interaction effect analysis
demonstrates that diabetes complications interact with each other, which makes
healthcare costs and health outcomes different between a case with one complication and
a case with two complications. Accordingly, we propose some useful suggestions. For
instance, as for how to decrease Medicare payments for outpatients with diabetes, we
suggest that the patients should often monitor their blood glucose level. We also
recommend that inpatients with diabetes should pay more attention to their kidney
disease, and use prevention to avoid such diseases to decrease the costs.
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CHAPTER I
INTRODUCTION

As healthcare reform has passed and is now law, Medicare will come under more
intense scrutiny in the healthcare industry. Diabetes is one of the most common chronic
condition diseases and the

7th

leading cause of death in America. It is necessary to study

the patients with diabetes in the Medicare insurance program. Although there are many
researchers who study such patients, few of them investigate those patients from a
statistical or data mining perspective. That is why we choose statistical analysis and data
mining of the Medicare beneficiaries with diabetes as the topic of this dissertation.
The primary purpose of this research is to apply statistical knowledge and data
mining algorithms to reduce the Medicare expenditures on diabetes beneficiaries,
improve the health outcomes of patients as well as to investigate the influence of
Medicare, part D since its introduction in 2006. In this chapter, we will briefly introduce
the background of this research. First, we will present the objectives of this dissertation.
Then we will review the previous research about diabetes patients within the Medicare
population and describe our main contributions. Next, we will make some assumptions
concerning the Medicare data. Then, we will introduce the basic concepts needed for this
study, including the types of diabetes and their oral medication treatments, Medicare
insurance and Medicare reform, the data sources and the medical codes. After we
introduce the basic statistical methodologies used in this dissertation, we will introduce

the outline for the rest of the chapters.

1.1 Basic Objectives of Dissertation
There are several objectives in this dissertation:
•

To see how to decrease Medicare reimbursements for both inpatients and
outpatients. We try to find out the most important factors influencing Medicare
payments through various statistical models and data mining algorithms such as
the decision tree model; we also utilize multivariate analysis to find the directions
of the relationships between the important predictors and the costs. In that way,
we propose strategies to decrease Medicare payments.

•

To see how to improve health care quality and outcomes. How to reduce the
mortality rate of patients and how to decrease the length of hospitalizations are
two concerns in this dissertation. We mainly employ various kinds of predictive
models to analyze how variables such as age, gender, and procedures affect the
outcomes so that we can provide methods to improve health outcomes.

•

To investigate the influences of the Medicare drug plan since it became effective
in 2006. We study the impacts through the usage of diabetes medications, the
cost-effectiveness of the drugs and the medical resources utilization.

1.2 Literature Review and Main Contributions
1.2.1 Literature Review
In most cases, patients with diabetes in the Medicare population are mostly
studied by medical methods, but occasionally, quantitative methods are also utilized.

2

Traditionally, statistical analysis is applied in three ways: cost analysis, outcomes
research and the study of the impacts of the implementation of Medicare, Part D. For cost
analysis, researchers only utilized simple statistical models to analyze the relationship
between the predictors and the dependent variables, costs. For example, Li et al. rI]
applied a 2-stage, least-squares model to estimate the effects of the predictor on Medicare
expenditures. Bhattacharyya et al. [2] employed a general linear regression model to
identify principal cost drivers among the identified cohort to the managed care system.
Herrin et al. [3] applied a hierarchical generalized linear model to analyze the relationship
between the costs and physicians and the general practice for Medicare diabetes patients.
For outcomes analysis, investigators employed basic statistical methods. For
instance, Kuo et al. [4] utilized the two-tailed t-test statistics to analyze the trend of care
practice and outcomes among the Medicare beneficiaries with diabetes. McBean et al. [5]
applied at-test when measuring the differences between the year 1999 and the year 2001
in diabetes care.
In terms of Medicare part D, only a few researchers have touched this topic so far
and they also used one basic statistical model for data analysis. For instance, Karaca et al.
[6] applied a multiple regression model to analyze how this drug plan affects the
beneficiaries' out-of -pocket costs. Another research group represented by Schmittdiel et
al. [7] used multiple logistic regression models to create adjusted percentages of
diabetes patients across demographic and health plan characteristics responding to the
survey questions about the implementation of the Medicare, Part D.

1.2.2 Main Contributions
Just as mentioned above, although some researchers performed simple statistical

3

analyses when they studied diabetes patients in Medicare, no one has yet investigated
those using data mining techniques. In this dissertation, we introduce the data mining
principles into the study of diabetes patients and make several contributions.
•

Introduce pattern discovery into patients' demographic characteristics and
diseases characteristics analysis.

•

Apply supervised machine learning, decision trees and neural networks to analyze
health outcomes.

•

In cost effectiveness analysis, instead of comparing two drugs or two clinical trial
methods, we compare differences of the two years for the same patients.

•

Introduce the quantitative methods into readmission risk analysis for diabetes
inpatients in Medicare.

1.3 Assumptions
Although we will make different hypotheses for different statistical models, we
also make some general assumptions in the entire dissertation.

•

In the dissertation, we are only concerned about type II diabetes patients in
Medicare and when investigating the influence of Medicare, Part 0, the research
subjects are restricted to those who join in the drug plan.

•

We do not consider the differences in severity of the diseases among the patients,
and when we compare two years of cases, we assume that the diseases of the same
patient will not become more severe in time.

•

We also assume that there are no differences in the costs and treatments among
different geographic regions.
4

•

We do not consider the discount rate for the QALY (Quality Adjusted Life Year)
for different years.

•

When it refers to medications, we only consider the generic drugs and do not
consider the brand name drugs.

1.4 Basic Concepts
1.4.1 Information about Diabetes, Its Types and Its Complications
Diabetes mellitus, or diabetes, is a group of diseases characterized by high blood
glucose levels that result from defects in the body's ability to produce or use insulin. It is
a devastating disease that greatly impacts long-term care and is the i

h

greatest cause of

death in the US. In recent years, diabetes has become a serious problem. According to the
CDC (the Centers for Disease Control and Prevention) [8] 23.6 million children and
adults had diabetes in the U.S.in 2007, and 12.2 million were over 60 years old.
There are mainly three types of diabetes [9]. Type I diabetes is usually called
juvenile diabetes since it is common in children and young adults. The cause for Type I
diabetes is that the body does not produce insulin. Type II diabetes, the most common
form of diabetes, occurs either because the body does not produce enough insulin or the
cells ignore insulin. Another type of diabetes is gestational diabetes, which is common to
pregnant women. However, this dissertation will only focus on type II diabetes in persons
65 years of age and older.
Diabetes can lead to many complications such as heart disease and renal failure,
high blood pressure and anemia. Statistics carried out by the American Diabetes
Association [10] showed that the probability of people with diabetes have heart diseases is
5

twice that of people without diabetes. Diabetes is the primary cause of end-stage renal
disease. The CDC [8] states that approximately 60% to 70% of those with diabetes have
mild to severe forms of nervous system damage, and severe forms of diabetic nerve
disease are a major contributing cause of lower-extremity amputations.
In addition, the co-morbidities often suffered by patients with diabetes can affect
each other. For example, diabetes is the leading cause of renal failure. The National
Institute of Diabetes and Digestive and Kidney Diseases study rII] showed that nearly 24
million people in the United States have diabetes; the Annual Data Report supported by
the United States Renal Data System [12] illustrated that nearly 180,000 persons are
suffering renal failure due to diabetes. Diabetic nephropathy likely contributes to the
development of anemia in diabetes patients. Anemia often develops early in the course of
chronic kidney disease in patients with diabetes and also contributes to the high incidence
of cardiovascular disease observed in diabetic patients.
Each year, it takes a large amount of resources to treat diabetes and its
complications, including organ dysfunctions and neurological disorders (Table 1.1) [13] .
According to the American Diabetes Association riO], a total of $174 billion was
expended on the treatment of diabetes in 2007; among the total medical expenditures
($116 billion), 23% ($27 billion) was for diabetes care and 50 % ($58 billion) was for
chronic diabetes-related complications. Therefore, it is fundamental to control diabetes.
Among all the measures to control diabetes, blood glucose monitoring is the best.
The Diabetes Control and Complications Trial funded by the National Institutes
of Health reported in 1993 [14] that intensive glucose control prevents or delays the eye,
nerve and kidney complications of type I diabetes (as cited in Glucose Control Cuts Risk
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of Heart Disease in Type I Diabetes); and DCCTIEDIC study illustrated that
intensive glucose control lowers the risk of heart disease and stroke by about 50 % in
people with type I diabetes. However, renal failure treatment is expensive, since the
expenditures for the treatment of this disease account for 30 % of the costs of the
treatment of diabetes, so it is essential to find and examine the factors that impact renal
failure in order to reduce the total charges of diabetes treatment.

Table 1.1 Health Care Expenditures Attributed to Diabetes (in millions of dollars)
Chronic Complications
Setting

Diabetes

Neurological

Peripheral

Cardio-

Hospital

1,535

3,115

vascular

vascular

2,719

20,790

3,285

36

23,473

58 ,344

Physician ' s

2,899

382

382279

1,004

323

899

3,830

9,897

Emergency

234

138

43

403

132

II

2,717

3,870

Hospital

842

75

135

317

87

130

1,321

2,985

Renal

Ophthalmic

General

Total

conditions

Source: Table 12(Abridged) in Economic Costs of Diabetes in the U.S. in 2007

Type II diabetes can be treated by oral medications [15]. The sulfonylureas such
as glyburide, glipizide, and glimepiride are all generic medications, which make them
inexpensive drugs for the management of Type II diabetes mellitus. Another class of
medication that has a similar mechanism of action to the sulfonylurea medications is the
meglintinides, including repaglinide (prandin) and neteglinide (starlix). Another drug
class is alpha glucosidase inhibitors, such as precose. Metformin, the only biguanide, is
recommended as a mainstay in therapy in patients with type II diabetes. When the above
medications become ineffective, insulin should be used alone or combined with other
drugs.

7

1.4.2 Medicare and Medicare Reform Related to Part D Plan
Medicare is the voluntary health insurance for people of age 65 or older, under
age 65 with certain disabilities, and any age with permanent kidney failure (called "EndStage Renal Disease"). It is required for any senior citizen on social security. It basically
consists of four parts, Part A (Hospital Insurance), Part B (Medical Insurance), Part C
(Medicare Advantage Plans) and Part D (The optional prescription drug program). Part D
uses competing private plans to provide beneficiaries access to appropriate drug therapies.
As of January 2008 [16], almost 90 % of Medicare enrollees had their prescription drugs
covered by the part D plan or other creditable sources. In this dissertation, we will not
study Medicare Advantage Plans because they are run by commercial insurance
companies instead of CMS (Centers for Medicare and Medicaid Services).
As the two acts, the Patient Protection and Affordable Care Act and the Health
Care and Education Reconciliation Act of 20 I 0 were signed into law; several changes
with the Medicare insurance program have taken effect since 2010. One of the significant
changes is about the Medicare, part D coverage gap or 'donut hole' [17]:
•

In 2010, if the beneficiary's expenditures reached the donut hole and enter the gap,
then slhe received a $250 rebate from Medicare.

•

From 2011 to 2020, if the enrollee's expenditures are in the gap, slhe will get a
50% discount on the total cost of brand name drugs.

•

Medicare will phase in additional discounts on the cost of both brand name and
generic drugs.

•

By 2010, the Medicare coverage gap would have been cancelled. Instead of
paying 100 % of the costs during the gap, the beneficiaries only needed to

8

pay for 25 % of the costs.
The Medicare drug plan was always a controversial issue since its introduction.
This time, the amendments to the plan make it again a topic of concern. Instead of
studying of the influences of cancelling the gap, we will investigate the influences
regarding the implementation of the drug plan due to limited data information.

1.4.3 Data Sources

In this research, we utilize two kinds of data sets. One is the CMS CCW (Chronic
Condition Data Warehouse) data [18] for the year 2004 and the other is the MEPS
(Medical Expenditure Panel Survey) data [19] for the years 2005 and 2006.
The CCW data are collected by CMS and provides researchers with Medicare
beneficiary, claims, and assessment data linked by beneficiary across the continuum of
care. Between the years 1999 to 2004, it covers a random 5% of the Medicare
beneficiary population each year. In this research, we use three data files for the year
2004, outpatienCbase_claims with 2,030,078 records and inpatients_base_claims with
244,299 items. Since both of them do not cover demography information, the dataset,
beneficiary_summary_file is needed.
The MEPS data, collected by the Agency for Healthcare Research and Quality,
is a class of survey data sets containing such information about medical services and
employers across the United States. In order to compare the differences in 2005 and
2006, we harness various kinds of data for these two years. They contain such
information as office-based visits, outpatient visits, inpatients, prescription drugs and the
full year consolidation. However, such data have some disadvantages. For instance, time
information is incomplete.
9

1.4.4 Medical Codes
Medical codes are very useful tools in medical billing and reimbursement. In this
study, we will use HCPCS (Healthcare Common Procedure Coding System) codes [20],
CPT (Current Procedural Terminology) codes [21] and ICD -9-CM (International
Classification Diagnosis, Clinical Modification, 9th edition) codes [22].
HCPCS codes are utilized by CMS for explaining the claims for payments. There
are two levels of HCPCS codes. Level I is comprised of CPT and Level II is a
standardized coding system that is used primarily to identify products, supplies, and
services not included in the CPT.
CPT codes are numbers used to represent medical procedures and services under
public and private health insurance programs. CPT codes are developed, maintained and
copyrighted by the AMA (American Medical Association). As the practice of health care
changes, new codes are developed for new services, current codes may be revised, and
old, unused codes are discarded.
ICD- 9-CM is an official system of codes used to stand for the diagnoses and
procedures associated with hospital utilization. Those codes are overseen and modified
by NCHS (the National Center for Health Statistics) and CMS. This system contains two
kinds of codes; one code is for the diagnosis of diseases and the other is for diagnostic,
surgical or therapeutic procedures. The common diagnostic ICD9-CM codes for diabetes
are shown below [23].
250.00-250.03

Diabetes mellitus without mention of complication

250.10-250.13

Diabetes with ketoacidosis

250.20-250.23

Diabetes with hyperosmolarity
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250.30-250.30

Diabetes with other coma

250.40 -250.43

Diabetes with renal manifestations

250.50 -250.53

Diabetes with ophthalmic manifestations

250.60-250.63

Diabetes with neurological manifestations

250.70-250.73

Diabetes with peripheral circulatory disorders

250.80-250.83

Diabetes with other specified manifestations

250.90- 250.93

Diabetes with unspecified complication

1.5 Basic Statistical Methodology
In this dissertation, several statistical methods and data mining algorithms are
utilized. The descriptive statistics such as kernel density estimation are applied to study
the distribution of the costs. The various kinds of statistical linear models such as the
general linear model and the generalized linear model are used to examine the
relationships between the predictors and the costs. Two-way interaction effect analysis is
used to analyze the influence of one diabetes complication on another complication in
costs and outcomes. The data mining algorithms such as the decision tree model and the
neural network model are employed for health outcomes and health quality analyses. The
survival model is utilized for our diabetes medication study. In addition, other theories
such as cost-effectiveness analysis in health economics are also utilized in this
dissertation.

1.6 Outline
The rest of the dissertation is organized as follows: Chapter II describes the data
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processing. Chapters III- IV introduce statistical models and supervised / unsupervised
machine learning. Chapters V-VI discuss Medicare costs and their influencing factors
for both inpatients and outpatients with diabetes, outcomes and readmission
risk factors of diabetic inpatients as well as 2-way interaction effects of diabetes
complications on costs and outcomes. Chapter VII investigates how the Medicare, Part D
program affects the usage and the cost effectiveness of diabetes medications. During the
discussion of our research in chapters V - VII, several theories applied in the study such
as survival analysis and cost-effectiveness analysis are also introduced. The last chapter
summarizes the dissertation results and gives the conclusions.
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CHAPTER II
DATA PREPARATION AND PROCESSING
Data preparation and processing is a key to successful analysis and accurate
results. Before we develop a statistical model or perform data mining analysis, we need to
preprocess the data to get them ready for study. In this chapter, we will briefly discuss
what techniques are utilized for data processing; that is, data validation, merging data,
data reduction, data transformation and some SAS functions used for data processing.

2.1 Data Validation
During the data validation (a.k.a. data cleaning), several things needed to be
checked: whether the information such as the diagnosis code is correct and whether the
variable type is correct. If some problem exists, then it needs to be dealt with by some
measure.

2.1.1 Dealing with Missing Values
It is very common that there are missing values in a large-size data set or a survey
data and they are needed to be examined in most cases. There are three ways to process
missing values: elimination, imputation and substitution.

1. Elimination
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Sometimes, if the missing values only account for a small percentage of the
sample, then they can be deleted without any processing. However, this method may
result in bias or inaccurate results if too many observations are eliminated.

2. Imputation
Imputation [24] is a prevailing approach of manipulating the missing values and
there are several different methods for imputation according to the types of missing
values. If the values are missing at random; that is to say, the probability of a missing
value appearing in one variable is not related to the probability of existing missing values
in another variable, then the values can be simply eliminated from the sample data.
However, this method may result in unnecessary elimination. If the values are completely
missing at random and can be judged in this way that the probability of missing values in
one variable is unrelated to the value of the variable itself or to values of any other
variable, then imputation is needed. One way to do this is MCMC (Markov Chain Monte
Carlo), which creates multiple imputations by using simulations from a Bayesian
prediction distribution for normal data.

3. Substitution
Substitution [25] is another approach of handling missing values. Sometimes,
according to the characteristics and types of variables, the missing values can be replaced
with some other values, such as the mode, the median, the mean, the maximum or the
minimum of the variables.

4. Our Approach
In our research, only the third method works to some extent. When we perform
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survival analysis about diabetes drug usage, considerable information about the day, the
month and the year of the prescriptions in the MEPS data is missing. Therefore, we deal
with missing values in this way: according to the rule of prescription of drugs, we set the
missing values of the variable, DAY to the first day of the month and the missing values
of the variable, YEAR to the year when the data were collected, but we eliminate an
observation whose month information is missing.

2.1.2 SAS Functions for Data Cleaning

1. Characteristic Functions
In our study, we utilize SAS characteristic functions to remove trailing blanks
before and after the nominal variables and to find certain letters in a string. The functions
[261 that we apply include LEFT, TRIM and TRANSLATE. For example, consider what
we do using the prescription drugs data.
/*To replace
'_' with a blank in the names, removes the
trailing blanks from theright-hand side of a variable value
and left justifies the variable value*/
NRXNAME=TRANSLATE(LEFT(TRIM(NRXNAME)), '_','

');

LEFT (TRIM(CONCAT[I] )); END; RUN;

2. Date Functions
We utilized the MDY function to return a date value from the numeric values for
month, day and year into a SAS date value. For instance, in our project about prescription
drugs usage, we use the following code to combine the three variables, DAY, MONTH
and YEAR into one variable, DATE.
DATE = MDY (RXMM, RXDD, RXYY);
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2.2 Merging Data
None of our data contains all the information we need; therefore, we have to
merge different data files into one file before our analysis. The tools for merging data are
SAS Enterprise Guide, the Base SAS data step and SAS SQL.

2.2.1 SAS Enterprise Guide
This is a user-interface-design SAS module in which we only need to click some
buttons, and then we can merge the different data sets together. For example, in the
project to discuss how to reduce the Medicare reimbursements for outpatients, we click
Filter and Query->Add table to join columns from revenue and beneficiary data sets to
generate another new data set containing beneficiary ID, HCPCS codes, total charges,
and so on.

2.2.2 Base SAS Data Step
Base SAS is the most commonly utilized method of merging data among the SAS
users. We employ it for data combination in several analyses. For instance, in analyzing
the outcomes of diabetes outpatients, we used the following SAS code:
PRoe SORT

DATA=SASUSER.IPCLUS; BY_CLUSTER_ ;

PROe SORT DATA= SASUSER.IPTCHDEM; BY _CLUSTER_;
DATA SASUSER.IPKDETCHDEM;
MERGE SASUSER.IPCLUSTER SASUSER.IPTCHDEM; BY _CLUSTER_;

2.2.3 SAS SQL
SAS SQL has some advantages over the base SAS data step; for one thing, before
merging the data by their common variables, we do not need to sort each data set by their
common variables. For another, the names of the common variables in different data sets
16

are not required to be the same. Consider a cost-effectiveness analysis of the diabetes
medications; for example, we can apply an SQL conditional inner join to merge the data.
/*Combine the life table and 2006 Medicare part 0
beneficiary table */
PROC SQL;
CREATE TABLE SASUSER.LE06 AS
SELECT *
FROM SASUSER.LIFETABLEl AS LT,
SASUSER.BCHWLQ06 AS BC
WHERE LT.AGE=BC.AGE06X;
QUIT ;

2.3 Data Reduction
After we get the different data sets into one data set, we need to reduce the data
size, if possible. There are several approaches: (1) sampling and partitioning (2) principal
component analysis (3) factor analysis (4) observations or variables selection.

2.3.1 Sampling and Partitioning
1. Sampling
There are mainly three types of data sampling methods [271: (I) simple random
sampling (2) stratified random sampling (3) cluster sampling.
(1) Simple random sampling: A sample is selected in such a way that every possible

sample of the same size is equally likely to be chosen. We can realize this through
clicking the Random Sampling button in SAS Enterprise Guide by choosing either the
number of observations or a percentage of the sample. We can also perform random
sampling through the SAS SURVEYS ELECT procedure.
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(2) Stratified random sampling: This sample can be obtained by separating the population
into mutually exclusive strata, and then drawing simple random samples from each
stratum. When we discuss the relationships between other diseases and renal failure, we
need to use this method to guarantee that all the rare occurrence events of renal failure are
selected in the large data set. We realize this through setting the sample node in
Enterprise Miner in this way [28]: set sample method to stratify, stratified criterion to
level based, and level selection to rarest level.
(3) Cluster sampling: This can be obtained by dividing the data into several groups or
clusters of elements. When we compare the differences between the different diagnosis
procedures in Medicare payments, we first cluster the procedures into several groups.
2. Partitioning

Before we build a predictive model in SAS Enterprise Miner, we often use the
Partition node to divide the sample into three smaller data sets: training, validation and
testing [29]. The training set is used to build a model. The validation data set is utilized to
ensure a model of good fit while the testing data set is applied for comparison to find an
optimal model.
2.3.2 Principal Component Analysis and Factor Analysis
Although principal component analysis and factor analysis are very popular
approaches, we apply neither of them in our analyses due to a very large data size.
Instead, we utilize sampling and clustering to reduce the sample size.
2.3.3 Observations or Variables Selection
Sometimes, not all the observations meet our requirements, or some variables
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have nothing to do with our predicted targets; therefore, we need to select observations or
variables. One method is to apply the KEEP or DROP statements and the following SAS
code demonstrates how to use them:
DATA SASUSER.IPCLUS(KEEP=_CLUSTER_ _ FREQ_
CLUS_DESC) ;
SET

RMSSTD

EMST.TEXT_CLUSTER;

In order to avoid duplicate observations, we can apply NODUPKEY:
PROC SORT DATA=SASUSER.COM06 OUT=SASUSER.NREP06 NODUPKEY;
BY DUPERSID DATE DATEI DATE2; RUN;

Another method to select observations (a.k.a. rows in SQL) and variables (a.k.a. columns
in SQL) is SQL conditional selection:
/*To sort out the diabetes patients*/
PROC SQL;
CREATE TABLE SASUSER.OBDIA05 AS
SELECT tl.DUPERSID, tl.OBICDlX, tl.OBICD2X, tl.OBICD3X,
tl.OBICD4X
FROM SASUSER.FILTER_FOR_QUERY_FOR_FILTER_FOR_ AS tl
WHERE tl.OBICDlX = '250' OR tl.OBICD2X = '250' OR
tl.OBICD3X =

'250' OR tl.OBICD4X = '250'; QUIT;

2.4 Data Transformation
The dominant method of transformations is the Box-Cox transformation [25],
which attempts to transform a continuous variable into an almost normal distribution.
This is achieved by mapping the values using the following set of transformations:

19

y A -1
(A)

Yi

={

_ I-

A

whenA *- 0

(2.1)

10g(Y i )whenA = 0

where A is the transformation parameter, and Yi is a continuous variable that needs to be
transformed. What we use data transformation for is to define dummy variables.
Sometimes, or defining procedures to new variables, we use 0-1 indicator functions and
the SAS code is shown below to get the new data shown in Figure 2.1.
IF(Recode_ICD9 EQ: '25000')
THEN R25000=1;
ELSE R25000=0;
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Figure2. 1. Newly-defined Variables

2.5 Other SAS Functions
Besides what was discussed above, we also apply some base SAS functions to
process the data sets. For instance, when we want to define a string containing all
possible diagnosis codes, we use the CATX statement, which concatenates character
strings, removes leading and trailing blanks, and inserts separators. The code is [26]:
DIAGNOSIS=CATX(' ',ICD9_DGNS_CDl, ICD9_DGNS_CD2, ICD9_DGNS_CD3
, ICD9_DGNS_CD4,ICD9_DGNS_CD5,ICD9_DGNS_CD6,ICD9_DGNS_CD7,IC
D9_DGNS_CD8, ICD9_DGNS_CD9, ICD9_DGNS_CDIO, ICD9_DGNS_CDI 1,ICD

20

9_DGNS_CD12, ICD9_DGNS_CD13, ICD9_DGNS_CD14,ICD9_DGNS_CD 15,IC
D9_DGNS_CD16) ;

When we want to convert all the values of a variable into observations, we utilize
the TRANSPOSE function and the code is shown below [26]:
PROC TRANSPOSE DATA=SASUSER.SORTMR06 OUT=SASUSER.TRANMR06
PREFIX=MED_; VAR NRXNAME; BY DUPERSID; RUN;

If we want to calculate the differences between different dates, we apply the
DATDIF functions:
DAYS=DATDIF (SDATE, EDATE, 'ACT/ACT');

In this chapter, we briefly discussed our approaches of processing the data and we
will elaborate them in detail in the later application chapters. The process of data
preparation contains more contents than what we introduced above. For example, it also
covers exploratory data analysis such as the sample mean analysis or a frequency count
study. We also utilize SAS to process the data during our study. Other preprocessing will
be discussed in later chapters.
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CHAPTER III
STATISTICAL LINEAR MODELS
Statistical models and the statistical methods associated with them are versatile
and robust. There are mainly two kinds of statistical models, one is the linear model,
which is simple and widely used and the other is the non-linear model. In spite of the
availability of highly innovative tools in statistics, the main tool of researchers remains
the linear model, which involves the simplest and seemingly most restrictive statistical
properties of independence, normality, constancy of variance and linearity. It can be
divided into several subgroups. (1) the general linear model, including the general linear
univariate model (ANOV A), the general linear multivariate model (MANOV A), the
regression model; (2) the generalized linear model, including the generalized
univariate/multivariate model; (3) the linear mixed model. The general linear model and
the logistic regression model can be thought of as special cases of the generalized model.

3.1 The General Linear Model
The general linear models are a class of linear models, and they can be
represented by the general linear regression model and ANOV A (Analysis of Variance).
As for the regression model, there are three subgroups, the simple linear regression model,
the multiple linear regression model and the logistic regression model.
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3.1.1 The Multiple Linear Regression Model
The regression model [30] is the oldest and most used model. It is also the most
understood model in terms of performance, mathematics, and diagnostic measures for
model quality and goodness of fit. The regression model has been applied to a very wide
range of problems in healthcare, finance or medical fields.
1. Assumptions

Understanding of the assumptions of a model is the key to successfully build a
model. The following are the assumptions for the multiple linear model:
•

The relationship between the response variables and the predictors is linear.

v

.1

•

The response vector

y =

Y2

nxl

is mutually independent, and the variance of

Yll
each element of the vector is cr 2, which is fixed and unknown.

•

The parameter vector {3pxl

=

is fixed and unknown.

{3,,-1
£1

•

The elements of the error vector £

=

£2

have the characteristics: (I) The

lOll

elements of the vector are independent from each other and identically distributed.
(2) The expectation of each element: E(£;)

element, var(£J

= 0; (3) The variance of each

= (72, where i=1,2, ... n; (4) cov(£; ,£) = 0 if i "*
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j.

2. Expressions
The matrix formulation of the linear multiple regression model is shown below

y = Xf3+£
where y,

/3,

E:

are as mentioned above, and the vector X

is the design matrix and I

(3.1)

= (I

= (l, 1, ... 1)T.

3. Model Development
In developing the model, predictors and the response variables are chosen and the
choice of algorithms to be applied is also considered. However, model development
belongs to the application of the model; we will discuss it in detail when presenting our
analyses. In the following model theories discussion, we will also postpone a discussion
of our analyses.

4. Assumption Diagnostics
The examination of basic assumptions is a fundamental procedure in building a
model and it is even more important than developing models themselves. The first thing
we need to do is to examine whether the model meets the assumptions. If a model does
not meet the basic requirements, then the model building is a failure. There are several
criteria that are used to check whether the assumptions are met.

I. Independence Test
The primary method of testing the independence of the response variables is the
Durbin-Watson statistic [31]. The test statistic can be written as:
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In the above expression, ei
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= Yi - Yi

(3.2)

is the residual of individual i, which is the

difference of the observed and predicted values of the response variable for individual i.
The value of d is always between 0 and 4. If d

= 2, it indicates that the model meets the

independence requirement and it also indicates that no autocorrelation exists.
II. Normality Test
There are three common measures to examine whether the residuals follow
normal distributions: (1) S-W (Shapiro - Wilk) test, (2) K-S (Kolmogorov - Smirnov)
test, (3) A-D (Anderson- Darling) test.
(1) S - W test [32]: The test can be conducted through a W statistic and it can be
calculated as follows:

W

=

(fa,x u))'
--,---I=_1_ _--'--11

(3.3)

~)Xi _X)2
i=1

In the above expression, XI, X2 ...
distribution;
aI, ... all

Xn

represent a random sample that follows a normal

x stands for the mean of the sample; X( 1), •• , X(n) are an ordered sample;

are constants generated from the means, variances and co-variances of the order

statistics of a sample of size n from a normal distribution; to be specific, they can be
calculated in this way:
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(3.4)

where E= (El, .. , En )T and the E/ s are the expected values of the order statistics of the
random sample and V is the covariance matrix of the order statistics. Whether the sample
meets normality can be judged by the value of W. The value of W is between 0 and 1.
Small values of W indicate that the sample does not follow a normal distribution, while
the value of close to 1 means normality.
(2) K-S test [33]: This test can be realized through calculating a D-statistic and the
process is shown below.
Test hypothesis: Ho: The sample follows a normal distribution
Ha: The sample does not follow a normal distribution
The D-statistic is defined as follows:
(3.5)

x

in which Dn is the largest vertical distance between the distribution function F(x) and the
empirical distribution function Fn(x); the empirical distribution function is defined as:
I

n

F,,(x)=-Llx<t
n i=1
,_.
where the xli;' s are ordered statistics, I

<.

\,_.\

(3.6)

is an indicator function, and its expression is

shown below:
I X,"" -- { 1 ('f Xi <
- X
o otherwise

(3.7)

The criterion of judging whether the sample follows a normal distribution is based on the
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value of the D-statistic. If the value of D is greater than the critical value, then the sample
does not follow a normal distribution.
(3) A- D test [32]: In the Anderson- Darling test, the statistic A is calculated and its
expression is shown below:
A2

= - n- S

(3.8)

where F is the cumulative distribution function and the variable S is defined in this way:
11

S

2i

I

= L---[logF(Yi)+log(l-F(YI1+,_i)]
i~1

(3.9)

n

If the value of A is smaller than the critical value, then the sample follows a normal
distribution.
If the model's requirements are met, then the fitness of the model is another vital

thing needed to be checked.

III. Autocorrelation Diagnostics

In statistics, the autocorrelation [34] describes the correlation between values of a
random process at different points in time and it can be defined as in (3.10).
Autocorrelation of the error terms often occur in time series data.

R(i, j)

= E(xi -J.1)(x j

-

J.1)

(3.10)

(Yi(Yj

In the above expression, if R( i,j) is well defined, then its values should lie in [-1,1].
x, J.1, (Y represent the value, the mean and the standard deviance, and i, j stand for two
different time points. The measure to examine the existence of the autocorrelation is the
Durbin-Watson statistic [31]. The basic rule is to compare the values of d to the lower
level dL.a and the upper level dU,a of the critical values at the significance a.

27

IV. Multicollinearity Diagnostics
Multicollinearity exists when the samples are not independent from each other.
The statistic, VIF (Variance Inflation Factor) [35], can be employed to test for it. The
variable VIP can be defined in (3.11).
1
VIF=-l-R~

(3.11 )

where R2 is the model variance, defined in (3.12), in which n is the sample size (a.k.a.
the number of observations), k is the number of predictors (a.k.a. the number of
coefficients) and the expression of I _R2 is tolerance.

i=i

R"

= __-,-,-k_ _

(3.12)

i=i

n-k+l
A high value of VIF indicates the existence of multicollinearity and a value greater than
10 means a serious problem.

V. Outlier Diagnostic
Outlier detection is also an important step to test whether the mode is good or not.
There are mainly four statistics [351 : (1) Leverage (2) Studentized deleted residual
(3) Dffits-statistic (4) Cook' D statistic.
(1) Leverage: It is called the hat diagonal, which is used to detect outliers among the

predictor variables. If we write a prediction model into matrix form as:
(3.13)
and if we use the least squares approach to get the minimizer with respect to coefficients
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[3, we get

/J and then we get the expression of the hat matrix H defined in (3.14).
(3.14)

The leverage,

hii'

is the

observation with an

h ii

ith

diagonal element of the hat matrix. As a rule of thumb, any

that meets the following inequality (3.15) is considered as a

leverage point and it has the potential to change the model. For a small sample, the
criterion is changed to an inequality (3.16).
h>2

k

II

h >3
II

-

k

+1
n

(3.15)

+1

(3.16)

n

In (3.15) and (3.16), n is the number of response variables and k+l is the number of
coefficients, [30.fJ1 ....[3k . The observation with the largest hii can be said to have the most
extreme predictor variables, while the observation with the smallest hii values might be
said to be the most typical.
(2) Studentized deleted residual: This residual is another useful tool to detect extreme
values of the observations and it can be calcuated as the same way for the standardized
residual (a.k.a. studentized residual), except without considering the /h observation. The
expression for the residual

ti

can be written as:
(3.17)

where ei is the residual for the i1h observation; MSE(i) is the mean squared error for the
regression model given that the
value

ti

t" observation is left out; hii is a leverage. If the

of an observation is greater than 2, then the observation is probably an outlier.
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(3) Dffits statistic [36]: Although some potential outliers may be detected by the above
two criteria, they may not affect the model. On the contrary, the DFFITs statistic can find
the outliers that actually have influence on the model. The statistic can be expressed as:
I

DFF
I

=t(~)2
I-h
I

(3.18)
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The observation whose DFFi meets the following inequality will be thought to be
influential.

[k+l

D F F; > 2~ -----;;--n-

(3.19)

Here, k and n have the same meaning as the above.
(4) Cook' D statistic: This is the most often used criterion for outlier detection. Its
expression is shown below and the signs in it have the same meaning as above.
(3.20)

Typically, if the value of Di is greater than 2, the observation should be investigated.
Through I - V, we discussed methods and criteria to examine whether the
assumptions of a model are met and we will utilize them for model diagnostics before
developing our models.

5. Model Evaluation [35J
I. Significance Test

R2 and Adjusted-R 2 are used to study the magnitude of effects. If both the

predictors and the response variables are continuous variables, then R2 will be a good
measure to demonstrate that the proportion of the variation in the dependent variable is
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accounted for by the explanatory variables. The rule is that the value of R2 varies from 0
to I, and the higher the value, the greater the effect. The definition of R2 is displayed in
(3.12). Unlike R2, the adjusted R2 (3.21) increases only if the new term improves the
model more than would be expected by chance and it can be defined as:
R2
adjusted

= 1- (1- R2)

n -I
n- k - 1

(3.21)

The F- test is often used for a model significance check (a.k.a. overall fit of the model)
and it can be calculated as:

k

F1k,n-k-IJ

= -1---""-R--=-2n - k-I

(3.22)

II. Goodness Test
One useful tool to check whether the model is good is the root MSE [37] and it
can be defined in this way:
n

"(V_ yA)2
~.I
I

RMSE=

i=1

n-2

(3.23)

Since the RMSE is a frequently-used measure of the differences between values predicted
by a model and the values actually observed from the parameter being estimated, the
smaller the value, the better the model.

3.1.2 Linear Logistic Regression Model
The linear logistic regression model is a special case of the general linear
regression model used when the response variable is dichotomous. Most of its
characteristics are similar to those of the general regression model; therefore, we will
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focus on its three unique parts in this section: analysis of the results, rare event and model
selection.
1. Expression

The logistic regression model (a.k.a. logit model) [38] is used for prediction of the
probability of occurrence of an event by fitting data to a logit function:
log(-P-)
1- P

= Po + pT X

(3.24)

where p is the probability and the odds ratio is expressed as:

odd=~

(3.25)

1- P

2 . Rare Event and Oversample

Rare event: If a target variable appears in a fraction of less than 10% in a large
data set, then it is a rare occurrence event. For instance, fraud rate and mortality rate are
two rare events with two values, 0 and 1.
Although the logistic regression model is a very useful model, there arise some
problems when the model is applied in rare event data. Gary King et al.(2001) [39]
demonstrated that the logistic regression model could greatly underestimate the
probability of a rare occurrence event and they suggested that all the rare target variables
should be included in the model to fix this problem.
What Dr. King suggested is an approach of oversampling, in which a data set is
stratified by the levels of a rare event variable and assigned different sample weights to
different levels. We can compensate for oversampling in two ways, one method is to use
the sample node in SAS Enterprise Miner as we mentioned in chapter 2 and another
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method is to employ the surveyselect procedure in SAS/BASE, which we will discuss in
chapter 6.
3. Model Selection

When developing the model, effect selection is often considered. The purpose of
the selection is to choose the predictors that are significant to the response variable and
the criteria for each selection vary from method to method. There are 3 main frequentlyutilized methods: (1) forward selection, (2) backward elimination, (3) stepwise selection.
(1) Forward selection: In this method, at the beginning, only the intercepts and the first n

explanatory effects are put into the model; then, another new effect significant at the level
a is input into the model. The process will continue until all the remaining effects
that are significant outside the model are imported. The criterion for the selected entry
is the score X2 statistic defined as:
(3.26)
where the Ho: hypothesis is defined as follows; 1= a~~); L is the log likelihood
function; PHD is the maximum likelihood estimation of the coefficient vector f3 under Ho:
and HS is the hessian matrix defined in the form:

a2f(P) a2f(P)
ap1 2 ap1ap2
2f(P) a2f(P)
a
S
H = ap ap2
ap;
1
a2f(P) a2f(P)
apkapl apnap2

a2f(P)
ap1apk
a2f(P)
aP2 apk

a2f(P)
apk2

In the above expression,f is a real-value function: f
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(XI ..... X n ).

(3.27)

(2)Backward elimination: In this method, at the beginning, all the effects are fitted into
the model; then, at each step, the least significant effect among those staying in the model
will be removed. The process will not stop until all the remaining effects are significant.
In this step, the results of the Wald test for individual parameters are examined.
(3) Stepwise selection: The process of this method is a combination of the above two
methods. At the beginning, only intercepts and n effects are in the model; then, another
significant effect will enter into the model in each step. However, during the process, if
some effect in the model becomes not significant, then it will be eliminated from the
model. The process will continue until no new effect can be input into the model or no
existing effect can be eliminated from the model.

4. Model Convergence
It is important to check whether the convergence criterion is met. The default
criterion by SAS is the relative Hessian convergence criterion with tolerance number [40]
and it can be expressed as follows:

(3.28)

where f(fJ) is the function with the k dimensional vector: fJ

=

[~IfJk J;

af(fJ) is the
afk (fJ)

gradient (a.k.a. first derivative) of fk ( the objective function at iteration k) ; and Hk is the
Hessian (a.k.a. second derivative) of the objective function at iteration k. The expression
of the Hessian for the function f(fJ) is similar to the one shown in (3.27).

5. Output Analysis
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I. Model Fit Statistic
Three criteria can be applied to examine the model fitness [40] (1) -2 Log L (Log
Likelihood), (2) AIC (Akaike Information), (3) SC (Schwarz Bayesian Information).
(l) -2 Log L: This is the most popular criterion used in hypothesis tests for nested models.

In this case,

mmeans the weight, f mmeans the frequency, Pm indicates the estimated

OJ

probability of the event, n is the total number, m is the number of successful events; then
for the

mth

event, the expression of the log likelihood for the binary target is:

(3.29)
(2) AIC: It is used for the comparison of non- nested models on the same sample and it

can be calculated as:
AIC = -2 LogL + 2 [(k -1) + s]

(3.30)

where k means the number of levels of the response variable and s stands for the number
of input variables.
(3)SC: It is another adjusted form of -2 Log L. The form of SC is shown below and the
parameters have the same meaning as before:
SC= - 2 Log L + «k-l) + s)

* log Cf.jj)

(3.31)

II. Analysis of Maximum Likelihood Estimates
There are two items in the output worthy of notice [401:
Estimate: It explains how the input variables affect the dependent variable, given that the
other predictors in the model are held constant.
95% Wald Confidence Limits: This is the Wald Confidence Interval (CI) of individual
odds ratio, given the other predictors is in the model. For a given predictor variable with a
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level of 95% confidence, we say that we are 95% confident that upon repeated trials, 95%
of the CI's would include the "true" popUlation odds ratio.

3.2ANOVA
Analysis of Variance is another popular tool among researchers. There are several
ways to divide ANOV A into different types. According to the structure of the data, it can
be divided into balanced and unbalanced ANOV A. According to the number of
dependent variables, there are ANOVA and MANOV A. According to the number of
predictors, there are one-way ANOV A (a.k.a. one-factor ANOV A), two-way ANOV A
(two-factor ANOVA) and multi-factor ANOV A. In our analyses, we only study one
response variable each time; therefore, we will not consider MANOV A, in which there
are two or more dependent variables. ANOV A can be thought of as a special case of a
linear model, and hence, it has many characteristics that a general linear model has.
Besides, with only a slight exaggeration, a multi-factor analysis is very similar to a twoway ANOV A. Therefore, in this section, we will focus on the special characteristics of a
one-way ANOV A and two-way ANOV A.

3.2.1 One-way ANOV A [41]
There are two ways of parameterizing ANOV A; one is the cell means model
while the other is the factor effects model. However, as the former is not as robust as the
latter one; we only explain the factor effects model in this section.
1. Assumption

The basic purpose of a one-factor ANOVA is to compare whether there is a
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difference between the means of the different groups. The assumptions of one-factor
ANOV A and two-factor ANOV A are the same:
• The population distributions should be normal, and have equal means .
• Variances across all of the levels should be equal.

2. Model Expression
Y.=I1+a+£.
I.}
I,j

I

(3.32)

where the notations related will be explained below:
N: total number of observations
ni

= 1,2, .. .r:

number of levels of factor x

nj =1,2, ... s: number of observations at each level i

_ _the mean for level i : 11i j=l

(3.33)

nj

~~Y.I,J

L.L.

the overall mean /-l :

i=l j=l

(3.34)

11=--'------N

the difference between the mean of the sample and the mean of x at level i,

3. Hypothesis
Ha: not all the fli are equal

4. Logic of ANOVA
There are two important parameters in this analysis. One is the sum of squares,
and the other is the F test. In this part, the notations have the same meanings as before.
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(l) Sum of squares: The total sum of squares of the model can be divided into the sum of

the among-group sum of squares and the within-group sum of squares:

SSG

Among- group sum of squares:

i

= n)

a

2

(3.35)

i

i=1

n

SSE

Within- group sum of squares:

=

II
i=1

111

Total sum of squares:

TSE

o

11

=I

i=1

-

(Yi ,)

-

(ai

+ 11))

(3.36)

= SSG + SSE

(3.37)

j=1

II,

I

(Yi ,)

-

11)2

j=1

(2) F test: The F-test is used for comparisons of the components of the total deviation and

it can be defined as the ratio MSG/MSE (defined in 3.38 - 3.40) where the p value is the
area of the tail outside the value given by the ratio. If it is small, then the significance
level is larger than the p-value and so we can reject the null hypothesis; it indicates that
the predictors are significant. A large F value indicates that there is more difference
between groups than within groups.
(3.38)

(3.39)

F=MSG
MSE

(3.40)

3.2.2 Two-way ANOVA [42]
A multi-factor ANOVA can be represented by the two-factor ANOVA; we will
discuss the two-way analysis for simplicity.
1. Hypothesis
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Main effect of factor A :

(Ji

= j1-j1i

where pj

= j1-j1j

where

Ha: not all the j1i are equal
Main effect of factor B:

Ho: fLl =fL2 ="'=fL j
Ha: not all the j1j are equal

Interaction effect:

where

)'i.j

= j1-j1j

Ha: not all the j1(i,)) are equal

2. Expression
The expression for two-factor ANOV A is:

fL)
(I,j

= fL + a + f3, + Y(,
1

I

')

1,1

(3.41 )

3. Sums of Squares
There are at least four types of sums of squares [40].

Type I sums of squares: This type of sums of squares is also called sequential sums of
squares. It can be computed as the decrease in the error sum of squares when the effect is
added to a model. Type I sums of squares are appropriate for balanced analyses of
variance in which the effects are specified in proper order and for trend analysis where
the powers for the quantitative factor are ordered from lowest to highest in the model
statement.

Type II sums of squares: Type II sums of squares can also be calculated by comparing
the error sums of squares for subset models. It is the reduction in the SSE due to adding
the effect to a model that contains all other effects except those being tested.

Type III sums of squares: Type III sums of squares is also referred to as the partial
sums of squares. Because they do not depend upon the order in which effects are
39
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specified in the model, this type is more popular and useful than type I sums of squares.
They can also be used for unbalanced designs.

Type IV sums of squares: Type IV sums of squares are used for designs with missing
cells. The results are not unique.

3.3 The Generalized Linear Model
The generalized linear models [431 are a class of linear models that includes the
Poisson regression model and the gamma model, etc. The model uses a nonlinear link
function to describe how the mean of a population is related to a linear predictor and
allows the dependent variable to follow any distribution belonging to the exponential
family of distributions (including many common distributions such as a normal
distribution, an exponential distribution, a gamma distribution, etc.). With the
introduction of GEEs (the generalized estimating equations) by Liang and Zeger [44], the
correlated data also can be fit into a generalized linear model. Therefore, the generalized
linear model can be used in more cases than the traditional linear model.

3.3.1 Assumption
The generalized linear model still assumes that the relationship between the
predictors and the response variable is linear. However, it has its own different
assumptions from the other linear models.
•

The distribution of the dependent variable is not necessarily a normal distribution.

•

The variance of the sample is constant for all observations.

•

The relationship between the mean of a sample and an input variable can be linked
through a nonlinear link function.
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3.3.2 Expression
The linear component of this model is the same as the general linear model. If we
use Yi to stand for an element of the response vector, J1i for the mean of Yi,

1

for the link

function, which describes how J1i is related to Yi, V(J1i) is a variance function with respect
to J1i, and 0" is the variance of Yi , then the expression for the model can be described as
follows:

v = xTfJ

Linear components:

-

I

(3.42)

I

Link function:

r(JlJ

= x~ fJ

(3.43)

Variance function:

()( v)

= ¢V (JlJ

(3.44)

-

I

Wi

3.3.3 Link Function for Different Distributions
The link functions vary from distribution to distribution. The differences among
these link functions are the range and scale of the probabilities they produce.
1. The General Linear Model

1

1 y-Jl

[ 2(

Distribution: normal:

f(y)=--exp - - - -

Link function: identity:

Y(Jl)

= Jl

Distribution: binomial:

fer)

= (: )Jl

Link function:

log itY(Jl)

.j2Jr()

()

)2]

fore -00,+00)

(3.45)

(3.46)

2. Logistic Regression

1

(1- Jl)'H, r

= O,l,2, ...n

(3.47)

= loge ~)
1- Jl
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(3.48)

3. Poisson Regression in Log-linear Model
A,k -'(

e

= - - , k = 0,1,2 ...

Distribution: Poisson:

f(k)

Link function:

log Y(j1)

(3.49)

k!

= 10g(j1)

(3.50)

4. Gamma Model with Log Link

Distribution: gamma

fey) = _1_( yv)V ex p(- yv), y E
r(v)y j1
j1

Link function:

log Y(j1)

(0,00)

= 10g(j1)

(3.51)

(3.52)

3.3.4 Output Analysis [38, 41]
1. Goodness of Fit
When evaluating the adequacy of the generalized liner model, one criterion, the
deviance of the model is often used. The rule is that the deviance is compared with its
asymptotic

l

with the same degree of freedom distribution to find the p-value; if the p-

value lies in a certain allowable range, then the model fits the sample well.

2. Type I analysis & Type III analysis
One fundamental application of the generalized linear model is to find out all the
prominent predictors to the dependent variable. The importance of the variables can be
measured by X2 , which presents the difference in deviances of fitted log likelihoods
between successive models. In other words, if the value of

l

for a variable is larger than

those of the other variables, then this variable is the most important variable to the
dependent variable.
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I. Type I Analysis
One special property of type I analysis is that its results depends on the order by
which the independent variables are input into the model. The analysis can be run in this
way such that at the beginning, only an intercept term is input into the model. In
subsequent steps, one of the additional effects enters into the model. During each step, a
likelihood ratio statistic is computed between successive pair of models. P-values are
calculated based on the asymptotic distributions of the likelihood ratio statistics. By
comparing the corresponding p-value for each variable to a significance level, we can
judge whether a variable is significant in the model.

II. Type III Analysis
A Type III analysis does not depend on the order in which the terms for the model
are specified. This analysis consists of specifying a model and calculating likelihood ratio
statistics for type III contrasts for each term in the model. Under this analysis, a
maximum likelihood statistic is calculated through constrained optimization under the
condition that the Type III function of the parameters is equal to 0 and can be defined as
below:
LR

= 2[L(/J) -

in which /J is the unconstrained estimate,
an asymptotic

l

jJ

L(P)]

(3.53)

is the constrained parameter estimate, with

distribution under the condition that the Type III function of the

parameters is equal to 0, with degrees of freedom equal to the number of parameters
associated with the effect. However, this analysis is time-consuming; it is recommended
that the researcher reduce the sample size before applying it.
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3.3.5 The Poisson Regression Model
The Poisson regression model is another common linear model with a count
variable as a response variable and it assumes that the dependent variable follows
a Poisson distribution.
1. Expression[45]

The frequently- used expression for the Poisson regression model is:
log(E(Y)

= log(t) + /Y X

(3.54)

where log(t) is an offset.

2. Adequacy of the model
After developing a Poisson regression model, adequacy of the model is the first
thing to check since overdispersion [46]often occurs in a Poisson regression model.
Overdispersion occurs when there is more variability than a model is expected to have.
Typically, if the deviance or Pearson's X2 , divided by the degrees of freedom, is
greater than 1, then the model may be overdispersed.
One approach of adjusting for overdispersion [47] derives from the theory of
quasi likelihood and the basic idea is as follows:
•

Import a scale parameter <1>, then E(y)

= f..l and Var (y) = <1>f..l; if <1> > I, then the

model is overdispersed.
2

•

<i> = Pearsonz [45], where N is the number of sample cases and p is the number
N-p

of parameters.
•

<1> is unknown, and therefore, under this modification, the frequently-used method
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called the Fisher-scoring procedure for the estimated covariance matrix is
changed from (X T WTy 1 (standard error) to <l>(X T WTyl, where W= diag (WI,
W2, ... WIl ).

This adjustment will be further discussed later in chapter 6.

3.4 The Generalized Linear Mixed Model
The generalized linear mixed model [48] is a statistical model that extends the
generalized linear model by incorporating a normally distributed random effect [49],
which is an effect whose levels are assumed to be selected randomly.

3.4.1 Assumptions
•

The relationship between the exploratory variables and the response variable is
linear. Otherwise, a non-linear mixed model should be applied.

•

The random effect should follow a normal distribution; otherwise, a hierarchical
linear mixed model will be employed.

•

The model cannot be used when the data are correlated.

3.4.2 Expression
The generalized linear mixed model can be defined in this way:
y

= Xf3+ZY+E

(3.55)

where X and Z are known design matrices, the error E - N(O,R); the random effect y
-N(O,G), where G, R are variance matrices. The model has the following properties:

•

1J=Xf3+Zy

(3.56)

is a linear predictor with combined fixed effects and random effects.
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•

E(yly)

=r- 1(XP + Zy) = f.1

(3.57)

r- 1 (.) is an inverse link function and its selection is typically based on the error
distribution.
•

Var(y)

=G

(3.58)

The variance function is used to model non-systematic variability.
(3.59)
where D is a diagonal matrix containing the variance functions and R means "R-side"
random effect and Var(y / y) is the variance matrix in a model with only R-side random
components.

3.4.3 Estimation Method
In the generalized linear mixed model, most estimation approaches also rest on
some likelihood principle. To obtain maximum likelihood estimates, we should maximize
the marginal likelihood shown below:
t(P, y)

= ff(yly)p(y)dy

(3.60)

3.4.4 Output Analysis
1. Assumptions
The generalized linear mixed model is a very complicated model and its output
analysis varies in different sample data. In our later research, we will utilize it for a
binary response variable, and hence we will focus on the logistic regression with random
effects. In this case, there are n (=s +t) groups of subjects, two properties (PI. P 2 ) and one
eventy. Suppose that s subjects are randomly selected to have property land t subjects
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have property 2. The purpose of the model is to compare the occurrence of the event for
the two properties among different groups. Therefore, the event that a subject is chosen to
have property 1 or 2 can be counted as fixed effects and the group effects are random
effects. We define the following terms:
•

nil and n i2 represent the number of subjects reported to have property I or 2 and

i stands for a group.
•

Pi! and

•

ri is a random effect such that Yillri - B( nil' Pil); Yi21ri - B(n i2 , Pi2).

Pi2

stand for the probability of the event occurring to property I or 2.

Pil

_

flo + fll + ri

(3.61)

= flo + fl2 + Y

(3.62)

and

log(--) 1- Pi!

and

10g(1

Pi2

- Pi2

)

2. Fitness Evaluation
Whether the model fits the sample can be judged through the fit statistics table,
which has three criteria, pseudo-likelihood, generalized X2 and generalized

l

divided by

its degrees of freedom. We consider the measure, X2 / OF. If its value is very close to I,
then it indicates that the model fits the sample pretty well.

3. Random Effects Prediction
In order to predict the probability of the random effects, two methods are utilized;
one uses prediction in the whole model, the other only rests on the fixed effects. In this
procedure, two kinds of predictions of probabilities are generated for each observation
(take one observation with property I for example) and they are shown below,
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I

E(.
A

.)

Yz! Yz
A

E(YiI

)

=

I
1+ exp{- Po
A

- p, - rJ
A

(3.63)

I

= 1+ exp{- PoA - p,A}'

(3.64)

3.5 Comments
Each linear model discussed here has its own unique characteristics and has
different applications. The logistic regression model is by far the most popular
classification model, extending the techniques of the multiple regression model to
research situations in which the outcome variable is categorical, especially for the target,
which is a binary variable. However, for a rare occurrence of mortality, adjustments need
to be made to the model. Analysis of Variance is often applied to compare the means of
different sample data, no matter whether the sample is balanced or unbalanced. It is
widely employed in sociology and psychology and so on. The generalized linear model
extends the applications of the general linear model to a dependent variable following a
non-normal distribution such as a gamma distribution or a Poison distribution as well as
to the correlated data. Therefore, it is a popular research tool in the cost analysis, which
often follows a gamma distribution and longitudinal analysis in the healthcare industry.
The generalized linear mixed model can be applied for dichotomous, ordinal and nominal
outcomes as well as ranked data. Therefore, it can be employed for assessing the trends in
disease rates, modeling counts or predicting the probability of occurrence in time series.
In this chapter, we briefly introduced the theories and methods related to our
analyses, most of which are utilized to study one dependent variable. So far, we have
only discussed cases when there exist linear relationships between the predictors and the
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response variables. What if the relationship between the exploratory variables and the
dependent variable is non-linear, or what if there is no specific predicted variable? In
those cases, we will employ supervised/unsupervised machine learning, which we will
introduce in the next chapter.
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CHAPTER IV
UNSUPERVISED /SUPERVISED MACHINE LEARNING
Machine learning [50] is a subfield of data mining, and it was conceived in the
early 1960's with the clear objective to design and develop algorithms and techniques that
implement various types of learning, mechanisms capable of inducing knowledge from
examples of data. Machine learning is widely applied to medical diagnosis, bioinformatics and object recognition in computer vision and so on. According to the causal
structure of the model, the learning can be divided into two types: 1. unsupervised
learning, II. supervised learning. Unsupervised machine learning includes:
•

Cluster analysis (e.g. means, hierarchical algorithms)

•

Association rules (a.k.a. market basket analysis)

•

Collaborative filtering

Supervised machine learning contains:
•

Classification trees (e.g. decision trees)

•

Regression analysis (including the logistic regression)

•

Neural networks

•

K-nearest neighbors

•

Rule induction

•

Support vector machine

We have already discussed some of the algorithms listed above, such as the
regression analysis in chapter III, and some of these algorithms we will not use in our
50
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research. Therefore, in this section, we will elaborate on cluster analysis, association rule
analysis, the decision tree model, the neural network model and rule induction.

4.1 Unsupervised Machine Learning
In unsupervised learning situations, all observations are assumed to be caused by
latent variables and there is no distinction between the independent and the dependent
variables. Although it does not have a target variable, it does have some purposes.
Unsupervised learning is primarily composed of two techniques: cluster analysis and
market basket analysis, which are often utilized in consumer market analysis or patients'
medical conditions analysis.

4.1.1 Cluster Analysis
The purpose of clustering techniques is to detect similar subgroups among a large
collection of cases and to assign the homogeneous observations into one cluster. The
clusters are assigned a sequential sequence number to identify them in results reports. In
most cases, it is performed to reduce sample size and to prepare for another analysis. The
primary algorithms of clustering are k-means clustering, EM (Expectation Maximization)
clustering and hierarchical clustering.
1. K -means Clustering

The k -means algorithm [24] is an old and simple method applied in cluster
analysis. The process can be operated in this way: first, a fixed number of clusters, k is
given; then, observations are assigned to those clusters so that the means across clusters
are as terms different from each other as possible. The difference between observations is
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measured in a distance measure such as Euclidean or Squared Euclidean.

2. EM Clustering
Expectation Maximization [51] is another algorithm for clustering and its goal is
to find the most likely set of clusters for the observations. The basis of this approach is a
body of statistical theory, called finite mixture, in which a set of probability distributions
represent k clusters. The technique consists of two steps, E-step (estimation) and M-step
(maximization).
E-step: to compute the conditional expectation:
Q(O;OU))

= Eo,"

(log L(O, y)1 Yo)

(4.1 )

M-step: to find thee, which maximizes the expectation:
A

(1+1)

A

o = arg max Q( 01 0

(TI

e

(4.2)

These two steps are repeated until

(4.3)

where L (0, y) is a likelihood function,
unknown parameter and

fJ U )

Q:e, (1)) is a conditional expectation,

e is an

is the estimate of the unknown parameter at iteration t >0,

and £ is a very small positive number.

3. Hierarchical Clustering
Hierarchical clustering [52] is another algorithm for clustering, in which Ward's
method is utilized. We first defined several terminologies, error sum of squares,
total sum of squares,

T

and

R2

and they are shown in Equations (4.4) - (4.6).
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Error Sum of Squares:

(4.4)

Total Sum of Squares:

(4.5)

2

T-8

R=r
In the above equations,

X ijk

(4.6)

denotes the value for the variable k in observation j belonging

to cluster i; Xik stands for the cluster mean for that variable;

x, denotes the grand mean

for that variable. Using Ward's method, the like units should be clustered together in each
step; therefore, the error should be computed and minimized (or if the selection criterion
is R2 instead, then it should be maximized) in each step. At the end of the process, a
single large cluster of size n will be formed. The process starts with all sample units in n
clusters of size 1. Then, the clusters or observations are combined in such a way to
minimize the error or maximize R2. In that way, n-l clusters are formed in the first step,
n-2 clusters are generated in the second step, and this process will not stop until all

sample units are combined into one cluster.

4. Comments
We apply the last two methods of clustering. The merit of clustering analysis is
that it is simple and easy to perform. It provides a quick way to explore the data structure
without providing an explanation or interpretation, especially if the objects are classified
into many groups. However, it cannot be used to predict either the relationships between
different groups or the relationships between the predictors and the predicted variables.
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4.1.2 Association Rule Analysis
Association rule analysis [53], often referred to as market basket analysis, is used
to investigate relationships or associations between specific values of categorical
variables in large data sets. This technique can be used to uncover hidden patterns in
large data sets, and hence, it is especially well suited for data mining.
1. Basic Rule

The goal of association rule analysis is to find subsets of variable values

Sf, S2 .. S/I·

such that the probability of each of the variables simultaneously assumes that a value
within their respective subsets,

(4.7)

is relatively large. If we apply dummy variables, and Xi stands for a variable,

xij

is the /"

observation of the variable Xi , i means a set of all items associated with the variable Xi,
S( J) is the support of f, and t is the lower support bound; then the formulation of the rule
IS:

iEI

iE!

(4.8)

and the purpose is to find all the item sets fm that meet the following condition:
(4.9)

2. Confidence, Support and Lift
According to the rules, a high support item returned can be partitioned into
two subsets, A and B such that
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{

AuB=!

(4.10)

AnB=¢

If A is the antecedent, and B is the consequence, then the confidence can be defined in
this way: given that event A occurs, the probability that B also happens is equal to

P(BI A)

= #of(A => B)

(4.11)

#A
The support is defined as the ratio of the number of both events, A and B, appearing
together compared to the number of total transactions:

peA n B)

= #of(A n

B)

# ofall

(4.12)

The lift can be written as the ratio of confidence and its expected confidence:

peL) _ _P_(B--,---iA_)
- E(Bi A )

(4.13)

When studying the associations between items, the confidence, the support and the lift
should be considered. The basic rule is that the higher the value of these three measures,
the stronger the relations.

3. Application
Association rule analysis is one of the popular marketing strategies; many
retailers utilize it to find potential customers and increase their response rate when they
mail their product catalogs to their targeted customers. In our research, we apply it to
medical procedures. For instance, we explore whether the patients receive procedures
related to heart disease along with what additional procedures and treatments are also
given to them.
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4.2 Supervised Machine Learning
Although unsupervised learning has some merits, it cannot be utilized for accurate
prediction. Therefore, supervised learning algorithms are frequently used. In our research,
we often employ the decision tree model, the neural network model, and the rule
induction model. We then compare these models to find the optimal one. In this section,
we will discuss these models.

4.2.1 Decision Tree Model
We can apply three algorithms to the decision tree model in SAS EM (Enterprise
Miner 6.2): (1) the default tree methodology in EM, (2) CHAID (Chi-square automatic
interaction detection), and (3) CART (Classification and regression tree).

1. The Default Algorithm
We first discuss the default methodology [52] for the decision tree model in SAS
EM; it is a little different from the other two algorithms. The main idea of this approach
can be explained in this way:
•

The split is based on some measures, either a node impurity measure or / test;
the F test criteria, i.e. the p- value can also be utilized.

•

If the node has many observations, then a sample is used for the split search.

•

If the target is binary, nominal or ordinal, then the sample should be as balanced
as possible.

•

If after consolidation, the number of possible splits is greater than the number
specified, then a heuristic search is used.

•

At the beginning of the heuristic algorithm, each consolidated group of
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observations is assigned to a different branch; then at each step, the two branches
are merged; the process will not stop until no group can be assigned.
2. CHAID Algorithm

The algorithm, CHAID [541. applied in decision tree model building, was
originally proposed by Kass in 1980. Although this method can be utilized for both a
continuous dependent variable and a categorical target, here, we discuss the latter .The
method consists of three steps: merging, splitting and stopping.

Merging step: In this step, a significant value

Umerge

should be defined at the beginning;

then, by the equations shown in (4.14) - (4.16), the variable X.2 and the p -value can be
computed. If the significance (i.e., p-value) for a given pair of categories is larger than
Umerge,

then it will merge the respective predictor categories; otherwise, the adjusted p-

value will be computed using the equation displayed in (4.17).
I (

I I 'It)
J

X2 =

j '=l

i=l

_(jJ)2
Ij

(fJ.Ij

(4.14)

where IJIj is the observed cell frequency, liJlj is the estimated expected cell frequency
for cell (xn= i, Yn= j) and there are i categories of predictor X and j categories of the
dependent variable Y.

(4.15)

(4.16)
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where Xd follows a

l

distribution with degrees of freedom d

= (1-

1)(1- 1). The adjusted

p-value is calculated as the p-value multiplied by fJ (defined in Equation (4.18)). Suppose
that the total number categories of X is I, and after several merges, r classes are left. If
2:'S: r < I, then

*f3

(4.17)

(r-k)!
k!(r-k)!

(4.18)

Padjustea P

/3= f(-l)k
k=JJ

Splitting step: In this step, the adjusted p-value of each predictor will be compared with
the user-defined a,plit. If the adjusted p-value is not greater than the

a'pIit,

then its

corresponding predictor is used for the split; otherwise, the node is the terminal one.

Stopping step: The splitting step will continue until no more splits can be performed.
During development, a tree with a binary target is generated by repeatedly using the
above three steps on each node starting from the root node using the CHAID algorithm.

3. CART Algorithm
The Classification and regression tree methodology [24] was first introduced in
1984 by UC Berkeley and Stanford researchers Leo Breiman et al. This algorithm can be
implemented in two cases: the classification tree is used for a categorical predicted
variable while the regression tree is used for a continuous predicted variable. The primary
techniques included in this algorithm are how to select splits and how to prune a tree [49].
(1) Selecting Splits: The rule of thumb is that the split at each node will improve the
predictive accuracy to the greatest extent. For classification trees, there are several
impurity measures, including

l, G2 or the Gini index (shown in (4.19)), among which the
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Gini index is the most frequently used criterion,

Gini(S) =

11

I

Pi Pi = 1-

I pJ
)=1

(4.19)

where S is a set containing n classes, and Pi is the relative frequency of class j in S. For
regression trees, a least squares deviation is most frequently used. If N w (S) represents the
weighted number of cases in node S,
i,

Ii

Wi

is the value of the weighting variable for case

is the value of the frequency variable, Yi represents the value of the dependent

variable, and yeS) is the weighted mean for node S, then a least squares deviation can be
computed as:
(4.20)

(2) Pruning Trees: For the CART algorithm, it is more important to prune back to find
the optimal tree than to find when to stop splitting. A tool called V-fold cross validation
can be used to prune a tree, and the process can be addressed in the following way:
•

Partition the entire data set into V folders.

•

Train V folders on different combinations of V-I folds and estimate the error for
the fold that is left out of the tree at each time.

•

Estimate tree accuracy based on the error measurements.

•

Find the design parameters to minimize the error.

•

Refit the tree using all of the data, the chosen parameters.

4. Comments
The CHAID algorithm can build non-binary trees, which makes it popular among
market researchers while the CART algorithm is always building binary trees. One of the
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characteristics of the decision tree model in SAS is that it can demonstrate the importance
of the variables. A rule of thumb is that the level where a variable lies indicates its
importance. The higher the level, the more vital the variable. In addition, compared to
other methodologies, the decision tree model has three primary advantages. First, it is
non-parametric and non linear and hence it does not require specifications of a data
distribution. Moreover, it can automatically group the missing values into one category
without preprocessing them. In addition, its output is easy to understand and interpret.
Therefore, the decision tree model is a very popular tool for decision makers.
4.2.2 Neural Network Model
The neural network model [55], often simply called Neural Nets, originated from
early understandings of the structure and function of the human brain. The type of the
model that we utilize is MLP (Multilayer perceptron), and the algorithm is back
propagation. In this section, we will focus on this algorithm and this type of neural
network.
Input
la),cr

llid-ticn

()Ulput

lay""

layer

Figure 4.1. A Feed-forward Neural Networks

1. Basic Rule
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As figure 4.1 [55] demonstrates, the structure of an MLP consists of neurons
organized in three layers: input layer, hidden layer and output layer. Weights Wu are
assigned to each connection between the input neuron and the middle neuron, and
between the middle neuron and the output neurons. With nonlinear transfer functions,
hidden neurons can process complex information received from input neurons and then
send processed information to output layer for further processing to generate outputs. The
whole process of MLP can be described in the following way:
Step 1: The inputs Xi are combined together to form a weighted sum of inputs and the
weights

Wi

of connecting links.

Step 2: A transformation is performed to convert the sum to an output via a transfer
function/, and a transformation can be expressed in Equation (4.21). Among all transfer
functions, the logistic function is the most popular one.
(4.21)

Step 3: Network output values are calculated and compared to the target values and the
weights of the connections are changed to produce a better approximation to the desired
output. The way of adjusting the weights is demonstrated in Equations (4.22).
nell'
Wij

=

old
Wij

+ .L\wij

old

= Wi;

dE
+ (-77a-)
ij

(4.22)

in which E is the objective function and 77 is the learning rate which controls the size of
the gradient descent step.
Step 4: The above step will repeat until the output is ideal.

2. Comments
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Besides MLP, there are several other types of neural networks such as auto neural
networks, linear networks, Bayesian networks, etc. A neural network can be thought of as
a complicated combination of regression models, but it is a powerful classifier. It can
handle problems with many parameters, and it tends to fit the training data well and thus
has low bias. Therefore, in most cases, this model outperforms other models. If it is the
optimal model, we should use another tool to express the information in an easilyunderstood way.

4.2.3 The Other Models
1. Rule Induction

Rule induction [29] is another tree-based algorithm for classification. It is mainly
utilized to improve the classification ofrare events. Usually rules are expressions of the
form:
({(attribllte-I, vallie-I) and (attribllte-2, vallle-2) and· .. and (aftribllte-n, value-n)
then (decision, value).

Some rule induction systems induce more complex rules, in which values of attributes
may be expressed by the negation of some values or by a value subset of the attribute
domain.

2. Memory-Based Reasoning
MBR (Memory- Based Reasoning) [52] tries to mimic human behavior in an
automatic way. MBR needs a distance measure to assign the dissimilarity of two
observations and a combination function to combine the results from the neighboring
points to achieve an answer. The distance measure is the k-nearest neighbor algorithm, in
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which the k- nearest neighbors are determined by the Euclidean distance between an
observation and the probe. By MBR means, it is easier to generate examples than to
generate rules, and hence this method is very attracti ve.

4.3 Data Mining Model Comparison
After developing various models, several measures [56] can be used to find the
optimal model, including the AIC (Akaike Information Criterion), the BIC criterion
(Bayesian Information Criterion), the ROC (Receiver Operating Characteri stic) curve, the
Lift Chart and the misclassification rate, etc. We have already discussed the first two
criteria in Chapter III, and hence we will introduce the other measures in this section.

4.3.1 ROC Curve
The ROC curve is a graph (shown in Figure 4.2, part of Figure 6.7) that measures
the predictive accuracy of a model. In a Cartesian plane, the x-axis represents the false
positive value (a.k.a. I-specificity) and the y-axis represents the sensitivity value. Each
point in the curve corresponds to a particular cut-off. The model where the ROC curve is
leftmost is the best model among the different models.
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Figure 4.2. The ROC Curve
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4.3.2 Lift Chart
A lift chart (displayed in figure 4.3[56] ) is another graph criterion of measuring
the predictive accuracy of models. The scored data set is sorted by the probabilities of the
target event in descending order; observations are then grouped into deciles. For each
decile, a lift chart can calculate the ratio between the result obtained with a model and the
result obtained without a model that is based on randomly selected records. In the chart, it
is represented by the horizontal base line. Lift charts show the percentage of positive
response or the lift value on the vertical axis. If the distance between a curve and the
base line is the greatest, then the model to which the curve corresponds is the best one.
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Figure 4.3. The Lift Chart

4.3.3 Misclassification Rate
When comparing the models, we often utilized the misclassification rate. We
divide the sample into decision regions Rill, for each class Ck • Misc1assification

'*

occurs if the input vector x belonging to C; is assigned to Cj , where i j , the
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misclassification rate can be computed as:
p",

=I

Jp(x,C)dx
R·

(4.23)

1"

The optimal model should be the one whose misclassification rate is the minimum.
Up to this point, we have discussed the basic data processing methodologies,
basic concepts and the primary theories or algorithms that we will often use in our
research. As we move into the chapters ahead, we will become immersed in studying
diabetes outpatients and inpatients in the Medicare population without further discussing
these theories and algorithms.
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CHAPTER V
COST ANALYSIS OF MEDICARE OUTPATIENTS
WITH DIABETES
Outpatients with diabetes use considerable Medicare resources, and hence it is
essential to take measures to reduce the costs. The primary purpose of this chapter is to
address this problem from prevention and medical services perspectives. We will first
introduce some knowledge about descriptive statistics and correlation analysis; then we
propose methods to decrease Medicare payments through analyses of claims data and
data from revenue centers for outpatients.

5.1 Descriptive Statistics
Descriptive statistics [57] are used to quantitatively describe the basic features of
the data in a study and they include four types: (l) measures of central tendency
including the arithmetic mean, median and mode, etc.; (2) measures of dispersion such as
the standard deviance; (3) measures of association such as odds ratio and correlations
coefficients; (4) a non-parametric analysis such as kernel density estimation. In this
section, we will talk about the last two types.

5.1.1 Kernel Density Estimation
In statistics, kernel density estimation [57] is a non-parametric way of estimating
the probability density function of a random variable. For our research, we use the
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univariate case. The kernel estimator for the univariate case can be defined as:

1
x-X.
f(x;h)=-LK(
')
nh ;=1
h
1\

II

where XI, X 2 , ... Xn are independent and identically distributed random variables;

(5.1)

f

is

the density function; K stands for some known density function and h is a smoothing
parameter called the bandwidth. As an illustration, given some data about a sample of a
population, kernel density estimation makes it possible to extrapolate the data to the
entire population. To better display the distribution, it is important to make sure that the
smoothness of the graph is reasonable, which is decided by the bandwidth. One simple
method to choose the optimal bandwidth is to find the minimum of the asymptotic mean
integrated squared error (AMISE, defined below) with respect to h,
R(K) 1 -4 4
"
AMISE= --+-(jkh R(f (x))
nh
4

(5.2)

2

where R(K)= jK (x)dx.

5.1.2 Pearson Correlation Analysis
Correlation analysis is a common method of studying the relations between two or
more variables. The typical measure for the linear relationship analysis is the Pearson
correlation coefficient. The Pearson Product-Moment Correlation coefficient r [58],
simply called the Pearson coefficient gives information about the degree and the
directions of how the two variables are related. Its computation is based on covariance
and its value range is [-1,1]. The values ±l mean that there exists a perfect positive or
negative linear relationship between the two variables; the intervals of [-1, - 0.75) or
[0.75, 1) indicate a high degree of correlation; the intervals of [-.25,0) or (0, 0.25]
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indicate a low degree of correlation; the value 0 means that there is no predictability.
When it comes to the sample analysis, the sample coefficient R is seldom utilized; instead,

R2 is frequently utilized to display the relationship between the dependent variable and
the predictors. The formula for rand R are shown below.

(5.3)

~)(Xi - ~)(Yi R=

i

J'L)X

i -

y))
(5.4)

X)2 ~:CYi - y)2

I

I

In the above two formulas, cov (x,y) denotes the covariance; f.1" f.1"

(j', 2 ,(j', 2

respectively

represent the expectations and the variances of the variables x. y; x, y denote the sample
mean of x and y.

5.2 Cost Analysis using Data from Revenue Center
In this section, we use data from the revenue center and demographic data for
diabetes outpatients in Medicare from the CMS CCW data [181 to find ways to decrease
the costs through the general linear model and the generalized linear model as well as
Pearson correlation analysis.

5.2.1 Kernel Density Estimation
After using Filter and Query in SAS EG (Enterprise Guide) 4.1 to select the
necessary variables and combine two data sets together, we perform KDE (kernel density
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estimation) to see the differences in the costs among different races. The SAS code and
the results are shown below:
PROC SORT DATA=SASUSER.RANSAMPLE
BY BENE_RAC E_CD

OUT=SASUS ER . SRANSAM ;

BENE_S EX_IDENT_CD ;

PROC KDE DATA=SASUS ER . SRANSAM ;
UNIVAR REV_ CNTR_ TOT_ CHRG_AMT/ GRIDL=O GRIDU=1500
METHOD=SNR OUT=SASUS ER.KDECHAR ; RUN ;
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FigureS.I. KDE of Costs among Different Races (Male)
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Figure 5.2. KDE of Costs among Different Races (Female)

Figures 5.1 & 5.2 visualize the distributions of the costs; the densities of costs for
males and females follow gamma distributions and all of them approach zero after 1500
dollars. The costs of the whites have a higher probability of being lower compared to all
other races. There exist differences between the males and the females; the densities
arrive at the peak when the costs reach 50 dollars for males and 100 dollars for the
females.

5.2.2 Statistical Model Analysis
We want to find the reasons for Medicare payments from diagnosis information
utilizing the linear statistical models. Prior to analysis, we used the One-Way Frequency
in SAS EG to find the top 20 procedures displayed in Table 5.1 [23].
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Table 5.1 Top 20 HCPCS Codes
82962

Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home
use
Routine venipuncture for collection of specimen(s)

2

GOOOI

3

97110

4

85025

5

85610

Prothrombin time;

6

80048

Basic metabolic panel

7

80053

Comprehensive metabolic panel

8

83036

Hemoglobin; glycosylated (A I C)

9

90999

Unlisted dialysis procedure, inpatient or outpatient

10

97530

Therapeutic activities, direct (one-on-one) patient contact by the provider (use of dynamic
activities to improve functional performance),

11

Q4055

Injection,

12

80061

Lipid panel

13

97116

Therapeutic procedures ;gait training (includes stair climbing)

14

97112

Therapeutic procedure,; neuromuscular reeducation of movement, balance, coordination,

Therapeutic procedure, therapeutic exercises to develop strength and endurance, range of
motion and flexibility
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and
automated differential WBC count

kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities
15

99212

16

93005

17

99213

18

A4657

Office or other outpatient visit for the evaluation and management of an established patient;
Physicians typically spend 10 minutes face-to-face with the patient and/or family.
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation
and report
Office or other outpatient visit for the evaluation and management of an established patient
physicians typically spend 15 minutes face-to-face with the patient and/or family.
Syringe, with or without needle, each

19

84443

Thyroid stimulating hormone (TSH)

20

71020

Radiologic examination, chest, two views, frontal and lateral;

Some of extracted 20 HCPCS codes are regular diabetes examination procedure
such as A1C test (HCPCS: 83036) and some of them are procedures needed by diabetes
complications such as an Electrocardiogram (HCPCS: 93005). The 20 codes are
recorded as binary 0-1 indicator functions in 20 columns with SAS coding. We can use
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Analyze->ANOV A->Linear Model with costs as the dependent variables; the newlygenerated 20 indicator variables were used as the class variables in the model. The results
are given below:
Table 5.2 Overall the General Linear Model Information
R-Square

CoefTVar

RootMSE

0.033549

434.3811

1737.414

REV _CNTR_TOT_CHRG_AMT Mean
399.9746

The r-square value is 3.3%, which means that 3% of the variability of the costs
can be explained by the above 20 factors. Although this is a small number, it gives us an
idea of what is significant. Table 5.3 shows that the 20 variables are significant to the
costs. However, since the distributions of the costs are gamma distributions, we should
also consider the generalized linear model with a gamma distribution.

Table 5.3 Type III Sum of Squares
DF
I
I

Type III SS
144951012755
135540500264

Therapeutic exercises to develop strength and endurance

I

76340503128

Blood count

I

Prothrombin time
Basic metabolic panel

I

Source
Blood glucose monitoring
Routine venipuncture

tc=omprehensive metabolic panel

Mean Square
144951012755

Pr>F
<.0001

135540500264

F Value
48019.2
44901.7

76340503128

25290.0

<.0001

60850533348

60850533348

20158.5

<.0001

57263486670
37054519078

18970.2
12275.4

<.0001

I

57263486670
37054519078

I

30419948211

30419948211

10077.5

<.0001

<.0001

<.0001

Hemoglobin; glycosylated

I

37500526373

37500526373

12423.1

<.0001

Unlisted dialysis procedure,
Therapeutic activities, direct patient contact by the

I

417296629150
34114806835

417296629150
34114806835
169829929901

138241
11301.5

<.0001
<.0001
<.0001

I
I

Injection
Lipid panel
Therapeutic procedure, gait training

I

Neuromuscular reeducation of movement, balance
office or other outpatient visit, typically 10 minutes
Electrocardiogram, (EGG)
Office or other outpatient visit, typically 15minutes

I

169829929901
26676907909

26676907909

I

29359815777
24582913341

29359815777
24582913341

I

20034618172

20034618172

I

13816375074

I

17996085232

13816375074
17996085232

56261.0
8837.49
9726.28

<.0001
<.0001

8143.79
6637.04

<.0001

4577.07

<.0001
<.0001

5961.72

<.0001

Syringe,

I

15385539003

6657.61
5096.90

<.0001

I

20096703187
15385539003

20096703187

Thyroid stimulating hormone
Radiologic examination

I

8767439243.1

8767439243.1

2904.47

<.0001
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Table5.4 Criteria for Assessing Goodness of Fit
Criteria For Assessing Goodness Of Fit
Criterion
DF
Value
ValuelDF
Deviance

9964

22374.1763

Scaled Deviance

9964
9964

12474.8191

Pearson Chi-Square
Scaled Pearson X2

9964

I

130667.2143
72854.0725

2.2455
1.2520
13.1139
7.3117

--

...

Log Likelihood

-63303.4243

In Table 5.4, the value of deviance divided by degree is 2.25.The value shows the
adequacy of this model, which means that the model fits the data reasonably well. In
Table 5.5, all the p values are smaller than 0.0001, indicating that all 20 variables are
statistically significant. The

l

value of 1070.13 for blood glucose monitoring represents

twice the difference in log likelihoods between fitting a model with only an intercept and
a model with an intercept and blood glucose monitoring. Similarly, every

l

value for

each variable represents the differences in log likelihoods between successive models.
The output shows that the X2 values for venipuncture and blood glucose monitoring are
the highest among all the X2 values; therefore, we conclude that blood glucose monitoring
and venipuncture have more important effects on the costs than any other treatments do.
Table 5.5 Type I analysis
LR Statistics For Type 1 Analysis
Source

2 *LogLikelihood

DF

Chi-Square

Pr> ChiSq

Intercept
Blood glucose monitoring

-131538.88
-130468.75

I

1070.13

<.0001

Routine venipuncture
Therapeutic exercises

-129441.88

I

<.0001

-129197.95

I

1026.87
243.93

Blood count

-128915.08

I

282.87

<.0001

I

346.35
143.88

Prothrombin time
Basic metabolic panel

.•.

-128568.73
.'-128424.85

---

I

---

<.0001
<.0001
<.0001

-------:--

Comprehensive metabolic panel

-128315.64

I

109.21

<.0001

Hemoglobin; glycosylated

-128081.87

I

233.78

<.0001

Unlisted dialysis procedure

-127823.38

I

Therapeutic activities, direct patients contact by the
Injection

-127633.20
-127565.57

I

258.49
190.18

I

67.63

<.0001
<.0001

Lipid panel

-127459.23

I

106.34

<.0001
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<.0001

LR Statistics For Type I Analysis
Source
Therapeutic procedure, gait training
Neuromuscular reeducation of movement, balance
Office or other outpatient visit, typically 10 minutes
Electrocardiogram, EGG

2*LogLikelihood
-127263.69

DF

Chi-Square

Pr > ChiSq

I

-127112.20
-127004.16

I

195.55
151.48

<.0001
<.0001

I

108.04

<.0001

-126952.54

I

51.62

<.0001

97.05
144.09

<.0001

Office or other outpatient visit, typically 15 minutes
Syringe

-126855.49

I

-126711.41

I

Thyroid stimulating hormone

-126640.03

I

71.37

Radiologic examination

-126606.85

I

33.18

--

-- --- ._- -..

~---~

c---

<.0001
<.0001
<.0001

Table 5.6 Pearson Correlation
Pearson Correlation Coefficients, N = 12158258

Blood glucose monitoring
Routinevenipunctureforco llectionspeci men( s)

coefficients
-0.05110
«.0001)
-0.04919
«.0001 )

In Table 5.6, the negative correlation coefficients between the total charges and
blood glucose monitoring and routine venipuncture indicate that if we increase the
monitoring and routine venipuncture, we can decrease the total charges.

5.3 Cost Analysis Using Claims Data
5.3.1 Newly-generated Predictors
In this section, we will analyze the relationships between the diagnosis and the
costs of outpatients with diabetes using the Medicare claims data from the CMS CCW
data warehouse [18]. In these data, diagnosed diseases or procedures appear in more than
2 columns; therefore, we use the method in [59] to get them into one column. First, we
use Filter and Query to select Claim ID and ICD9_DGNS_CDI to generate a new data
set that contains two columns, and change the name ofICD9_DGNS_CDI to ICD9. It is
the same for the left nine ICD9_DGNS_CDn and six ICD9_PRCDR_CD n to generate 16
Tables. Then, we open one Table, and use Data - >Append Table; after that, the ICD9
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Table (Figure 5.3) is generated. This is followed by Describe->One-way
Frequencies to find the top 20 ICD9 codes as displayed in Table 5.7.
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Figure 5.3. ICD9 Table

Table 5.7 Top 20 ICD9 Diagnosis Codes
ICD9

4019

Diagnosis
Diabetes mellitus without compli cation type ii or unspecified type not
stated uncontrolled
Unspecifi ed essenti al hypertension

585

Chronic kidney di sease (ckd)

629

2.47

V5861

Long-term (current) use of anticoagul ants

509

2.00

2724

Other and unspecified hyperlipidemia

42731

Atri al fibrillati on

25000

Frequency

Percent

2264

8.90

135 1

5.3 1

508

2.00

469

1.84

2859

Anemia unspecified

452

1.78

4280

Congesti ve heart failure unspecifi ed

429

1.69

V5869

Long-term (current) use of other medi cat ions

402

1.58

28521

Anemi a in chroni c kidney di sease

357

1.40

4011

Benign essential hypertension

339

1.33

2720

Pure hyperchol esterolemia

3 14

1.23

41400

Coronary atherosclerosis of unspec ifi ed type of vessel nati ve or graft

296

1.1 6

25001

Diabetes mellitus without complication type i not stated as uncontroll ed

244

0.96

5990

Urinary tract infecti on site not spec ified

232

0.9 1

2809

Iron defi ciency anemi a unspec ified

230

0.90

2449

Unspecified acquired hypoth yroidism

225

0.88

496

Chronic airway obstruction not elsewhere classified

2 10

0.83

25002

Diabetes mellitus without complication type ii or un specifi ed type

203

0.80

78079

Other malaise and fati gue

194

0. 76

---

--

Next, we process the data to get the data (Figure 5.4) ready for analysis.

75

R4273

327.42
2~.00

WWNIiVWv
WWNViVWb
WWNViVWb
WWNViVWb
WWNViVWO
WWNViVWO
WWNViVWR
WWNViVW£

2fIl.94
163.00
:£.1.50
1ll.00
140.00
41000
2446.00

0

Figure 5.4. Newly-generated Data for GLM

5.3.2 Statistical Model Analysis
After the assumptions diagnostics, the generalized linear model is developed, with
the costs as the predicted variable and the newly-generated variables as the input
variables. The results are given in the following Tables.
Table 5.8

Overall Mode Information

Model Information
Data Set

WORK.SORTIEMPTAB
LESORTED

Distribution

Gamm a

Link Function

Log

Dependent Variable

CLM_TOT_CHRG_AMT

Claim Total Charge
Amount

Table 5.8 gives information about distribution of the response variable, the link
function. In Table 5.9, the value of deviance divided by degree is 2.32, and the scaled
deviance divided by degree is 1.26. These two parameters demonstrate the adequacy of
this model, which means that the generalized linear model fits the data reasonably well.

Table 5.9 Criteria for Assessing Goodness Fit
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Criteria For Assessing Goodness Of Fit
Criterion

DF

Value

ValuelDF

Deviance

9980

23196.7333

2.3243

Scaled Deviance

9980

12550.5608

1.2576

Pearson Chi-Square

9980

79786.4792

7.9946

Scaled Pearson X2

9980

43168.3655

4.3255

-75829.4983

Log Likelihood

Table 5.10 Type lAnai ysis
LR Statistics For Type 1 Analysis
Source

2*LogLike-

DF

ChiSquare

Pr

Intercept

-154184.45

R25000_Max Diabetes mellitus without complication type II or
unspecified type uncontrolled
R4019_Max
Unspecified essential hypertension

-154160.76

I

23.68

<.0001

-154078.23

I

82.53

<.0001

R585_Max

-152265.81

I

1812.42 <.0001

RV586 I_Max Long-term (current) use of anticoagulants

-152018.52

I

247.29 <.0001

R2724_Max

Other and unspecified hyperlipidemia

-151969.30

I

49.21

<.0001

R4280_Max

Congestive heart failure unspecified

-151953.57

I

15.74

<.0001

R4273 I_Max Atrial fibrillation

-151889.81

I

63.76

<.0001

RV5869_Max Long-term (current) use of other medications

-151886.98

I

Chronic kidney disease (ckd)

2.82

0.0929

--_._.-

._----

I

6.69

0.0097

-151782.39

I

97.91

<.0001

R28521_Max Anemia in chronic kidney disease

-151737.71

I

44.68

<.0001

R2720_Max

-151736.64

I

1.07

0.3014

-151731.99

I

4.65

0.0311

-151731.98

I

0.01

0.9287

R25001_Max Diabetes mellitus without complication type i not
stated as uncontrolled
R78079_Max Other malaise and fatigue

-151729.57

I

2.41

0.1203

-151729.57

0

0.00

R2809_Max

-151708.85

I

20.72

R2859_Max

Anemia unspecified

-151880.30
----

R4011_Max

---- . _ - - - - -

Benign essential hypertension

Pure hypercholesterolemia

R41400_Max Coronary atherosclerosis of unspecified type of
vessel native or graft
R5990_Max
Urinary tract infection site not specified

Iron deficiency anemia unspecified
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f - - _ ..

<.0001

LR Statistics For Type I Analysis
Source
R2449_Max

Unspecified acquired hypothyroidism

R496_Max

Chronic airway obstruction not elsewhere
classified
R25002_Max Diabetes mellitus without complication type ii or
unspecified type uncontrolled

2*LogLike-

DF

-151707.74

I

ChiSquare
1.11

0.2922

-151698.50

I

9.24

0.0024

-151659.00

I

39.50

<.0001

Pr

Table 5.11 Variables Significant to the Model
Diabetes mellitus without complication type II or unspecified
type uncontrolled
Unspecified essential hypertension
R585_Max
RV5861_Max

Chronic kidney disease (ckd)
Long-term (current) use of anticoagulants
Other and unspecified hyperlipidemia
Congestive heart failure unspecified

R42731_Max

Atrial fibrillation

R2859_Max

Anemia unspecified

R4011_Max

Benign essential hypertension

R28521_Max

Anemia in chronic kidney disease

R78079_Max

Coronary atherosclerosis of unspecified type of vessel native or
graft
Other malaise and fatigue

R2809_Max

Iron deficiency anemia unspecified
Chronic airway obstruction not elsewhere classified
Diabetes mellitus without complication type ii or unspecified
type uncontrolled

Type I analysis shows that the following factors (shown in Table 5.11) are
statistically significant to the model. Since the

l

value for chronic kidney disease ranks

the first among all the values (shown in Table 5.1 0), kidney disease is the most important
variable related to the costs.
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Since chronic kidney disease has the most important effect on the costs and
chronic kidney disease counts for a large percentage of renal failure, the logistic
regression in Enterprise Miner will be used to analyze the relationships between renal
failure and the other diseases vital to the costs. Before that, a binary variable, Renal is
generated using 0-1 indicator functions. The following steps are conducted in Enterprise
Miner. First, R (Renal Failure) is set as the target and the variables are set on binary level.
Then, a sample node is added and connected to the data; and the Stratify Method is used,
choosing Level Based as the stratified criterion and Rarest Level in the Level Based
options. The results are as shown in Tables 5.12 - 5.15.
Table 5.12 Misclassification Rate
TARGET

Fit

R_Max

Statistic Label

Train

Validation

Test

Misclassification Rate

0.38596491

NaN

NaN

Table 5.13 Type 3 Analysis of Effects
Effect

F
I

D

Wald
ChiSq
0.028

Pr>
ChiSq
0.866

I

1.131

0.288

I

0.360

0.548

I

0.027

0.868

I

4.708

0.030

Benign essential hypertension

I

0.264

0.607

Coronary atherosclerosis of unspecified type of vessel
native or graft
Atrial fibrillation

I

0.012

0.910

I

0.151

0.697

Congestive heart failure unspecified

I

0.226

0.634

Chronic airway obstruction not elsewhere classified

I

0.562

0.453

Chronic kidney disease (ckd)

I

0.428

0.513

Urinary tract infection site not specified

I

2.596

0.107

Long-term (current) use of anticoagulants

I

O.fXl

0.929

Long-term (current) use of other medications

I

0.015

0.902

Unspecified acquired hypothyroidism
Diabetes mellitus without complication type ii or
unspecified type not stated as uncontrolled
Diabetes mellitus without complication type i not
stated as uncontrolled
Diabetes mellitus without complication type ii or
unspecified tvpe uncontrolled
Anemia unspecified
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-------

-------------

The misclassification rate in Table 5.12 is 0.386, which is accepted. The results in
Table 5.13 indicate that only unspecified anemia is significant to renal failure as only its
p-value in the Type 3 analysis is less than 0.05 out of the 15 diseases that are considered
for renal failure. The odds ratio for Anemia in Table 5.14 shows that if the diagnosis is
not anemia, then the chance that it is related to renal failure is only 9 % of the probability
that it is Anemia. Hence, Anemia has the most prominent relationship to renal failure.

Table 5.14 Odds Ratio Estimates
Diagnosis

Effect

Point
Estimat
0.745

R2449 _Max 0 vs I

Unspecified acquired hypothyroidism

R25000_Max 0 vsl

Diabetes mellitus without
complication type ii or unspecified

2.057

R25001 - Max 0 vsl

0.602
0.840

R2859 _Max 0 vs I

Diabetes mellitus without
complication type i not stated as
Diabetes mellitus without
complication type ii or unspecified
Anemia unspecified

R4011 - Max 0 vs I

Benign essential hypertension

0.562

R41400_Max 0 vs I

Coronary atherosclerosis of
unspecified type of vessel native or

1.145

R4273 1- Max 0 vsl

Atrial fibrillation

1.551

R4280_Max 0 vs I

Congestive heart failure unspecified

0.704

Chronic airway obstruction not
elsewhere classified

0.402

Chronic kidney disease (ckd)

0.626

Urinary tract infection site not
specified
Long-term (current) use of
anticoagulants
Long-term (current) use of other
medications

0.121

R25002_Max 0 vs I

R496_Max

o vs

R585_Max

°

I

vs I

R5990_Max 0 vs I
RV5861 - Max 0 vsl
RV5869_Max 0 vsl
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0.093

1.139
0.794

Table 5.15 Event Classification Table
Data Role

Target

False Negative

Train

R_Max

32

True
Ne.l(ative
45

False Positive

True Positive

12

25

Table 5.15 shows that the false negative rate is 32 %, which means that it is 32%
likely for the model to predict that renal failure is not occurring when it in fact is; the
false positive rate is 12, which means that it is only 12 % likely to predict the diagnosis of
renal failure when it actually does not occur. Since a false negative is more critical than a
false positive, the model is fairly good.
Just as the results show, the model probably needs improving; hence, it is
necessary to utilize another model to analyze the relationship. Next, we utilized the
generalized linear mixed model, in which the GLIMMIX procedure in SAS can be used,
selecting Renal as the response variable, which is a binary variable; selecting Ane
(Anemia), Hea (Heart disease) and Unctrl (Uncontrolled diabetes) as the classification
variables; analyzing Ane and Hea in the fixed effects while analyzing Unctrl in the
random effects. The least-squares means for Ane and Hea are also used. The following
SAS code is used.
PROC GLIMIX DATA=SASUSER.RENAL;
CLASS HEA ANE UNCTRL;
MODEL RENAL=ANE HEA/DIST=BINARY LINK=LOGIT;
LSMEANS ANE HEAl;
RANDOM UNCTRL; RUN;

The model results of this analysis are shown in Table 5.16. In Table 5.17, the first
two measures indicate that the model is statistically significant; and the third one
demonstrates that the model fits the dataset very well.
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Table 5.16 Overall Information
Model Information
Data Set

SASUSER.RMIXW

-----

Response Variable

Renal

Response Distribution

Binary

Link Function

Logit

Variance Function

Default

Variance Matrix

Not blocked

Estimation Technique

Residual PL

Degrees of Freedom Method

Containment

Table 5.17 Fit Statistics
Fit Statistics
-2 Res Log Pseudo-Likelihood

180738.80

Generalized Chi-Square

110055.61

Gener. Chi-Square / DF

11.01

------ -

Covariance Parameter Estimates
CovParm

Estimate Standard Error

Unctrl

8.21 E-22

------

Table 5.18 Type 3 Analysis for Fixed Effects
Type III Tests of Fixed Effects
Effect

NumDF

Ane

1

Hea

1

DenDF

F Value

9996

------

3.68

t - - - - - - ----

9996

6.77

Pr>F
0.0551

---------

0.0093

Table 5.19 Least -square Means Analysis
Ane Least Squares Means
Ane

Estimate

Standard

DF t Value

Pr> It I

0

4.7986

0.2116

999 22.67

<.0001

1

4.0978

0.3677

999 11.14

<.0001

Hea Least Squares Means
Hea

Estimate

Standard

DF

t Value

Pr> It I

0

4.9771

0.1895

999

26.26

<.0001

1

3.9192

0.4000

999

9.80

<.0001

- - - - - - - - 1------- I--
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Table 5.17 lists the covariance parameter estimates for a random variable. The
variance for Unctrl is rather small and so the variable is significant to the model. The
output in the Type 3 analysis (TableS. 18) shows that both anemia and heart disease are
significant to the model. Table 5.19 lists the information about the least-square means.
The output shows that the estimate mean for anemia is 4.0978 and the standard error is
0.3677, while the value for heart disease is 3.9192 and its standard error is 0.4.
Therefore, the two diseases are almost equally important to renal failure.

5.4 Conclusion
After this analysis, we can draw the conclusions that in order to decrease
Medicare costs, we should often monitor blood glucose level of diabetes outpatients and
we also should emphasize diabetes prevention. In addition, chronic kidney disease
affects the charges the most. Finally, we should monitor heart disease and anemia of the
diabetic outpatients with renal failure.

In this chapter, we focus on outpatients with diabetes in the Medicare population;
in next chapter, we will study inpatients with diabetes.
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CHAPTER VI
COST ANALYSIS AND OUTCOMES RESEARCH FOR
MEDICARE INPATIENTS WITH DIABETES
In the previous chapter, we conducted a cost analysis of diabetes outpatients in
Medicare. The analyses of inpatients encompass more than those of outpatients. In this
chapter, based on the inpatient claims data and demographic data from the CMS CCW
data[ 18], we will start a cost analysis among different races or different complications of
diabetes; then, we will perform association rule analysis of different procedures. Next, we
will use various kinds of supervised learning algorithms to study the outcomes and a
readmission analysis of inpatients and we will end up with two-way interaction effects
analysis of diabetes complications.

6.1 Cost Analysis
6.1.1 Inpatient Costs among Different Races
At the beginning, we study the general cost distributions among different races
using kernel density estimation (Figure 6.1). Before the value of 40,000 dollars occurs,
North American natives> Whites> Blacks> Hispanics in terms of densities for costs, and
all of them spend more than Asians; while after that point, Asians cost more than the
other races.
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Figure 6.1. KDE of Total Charges among Different Races
6.1.2 Costs among Different Diagnosed Diseases

In this section, we want to see how different groups of diagnoses affect the costs.
Before that, we define a string containing all possible diagnosis codes using the CATX
statement in SAS.

0.1284052
0.0362
0.1828

0.1266924 ...

1276

0.1276

0.1260251 ..

1515

0.1515

0.1

790

0.079

Figure 6.2. Clusters of Diagnoses
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0.0988086 ...

0.1176632

After conducting clustering analysis with the E-M algorithm using SAS Text
Miner, we get the results displayed in Figure 6.2. To view how the groups of diagnoses
affect the total charges, we perform kernel density estimation.

Table 6.1 Translations for the Clusters
Cluster
number

Diagnoses

Cluster label

Unspecified Obesity, Schizoaffective disorder, Diabetes
mellitus without mention of complication, Tobacco use
disorder, Other and unspecified hyperlipidemia

2

Old myocardial infarction, Of native coronary artery,
Aortocoronary bypass status, Of unspecified type of vessel
or native or graft, Percutaneous transluminal coronary
angioplasty status

3

Other and unspecified angina pectoris, Other specified
cardiac dysrhythmias, Other persistent mental disorders due
to conditions classified elsewhere, Of native coronary artery,
Pure hypercholesterolemia
Unspecified Essential hypertension, Diabetes mellitus
without mention of complication, Unspecified
hypothyroidism, Osteoarthrosis which unspecified whether
generalized or localized, Depressive disorder

4

Diabetes

Heart disease

Heart disease
vascular disease

vascular disease
Diabetes

5

Diabetes with neurological manifestations, Background
diabetic retinopathy, Diabetes with ophthalmic
manifestations, Diabetes with ophthalmic manifestations,
Other and unspecified hyperlipidemia

Ophthalmic disease
Neurological disorder

6

Unspecified Acute renal failure, unspecified Congestive
heart failure, Obstructive chronic bronchitis with
exacerbation, Unspecified Hypertensive chronic kidney
disease, Pneumonia

Heart disease
Kidneydisease

7

Mitral valve disorders, Diabetes mellitus without mention of
complication, unspecified Congestive heart failure, Other
primary cardiomyopathies, Atrial fibrillation,

Diabetes
Heart disease

8

Alzheimer's disease, Urinary tract infection, unspecified
Anemia, Volume depletion, Pneumonia

9

Diabetes mellitus without mention of complication,
Esophageal reflux, Other and unspecified hyperlipidemia,
Unspecified Essential hypertension, Pure
hypercholesterolemia
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Others
Diabetes
vascular disease
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Figure 6.3. KDE of Total Charges for Diabetic Inpatients by Clusters (Male)
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Figure 6.4. KDE of Total Charges for Diabetic Inpatients by Clusters (Female)

Figures 6.3 and 6.4 demonstrate that the distributions of the costs for male
inpatients are different from the ones for females. The clusters yield the relationships in
terms of ordering. For males, before the first cutpoint occurs at 19,200 dollars, in terms of
density, cluster #5 is much greater than the other clusters; between the cutpoints of
19,200 dollars and 33,000 dollars, the ordering of estimated density is 1,4, 5,9>2,3>6, 7,
87

8. After 33,000 dollars, there are no differences among all clusters. The graph for female
inpatients shows the costs in terms of ordering is 9>5>2>1,3>7,8>4,6 before the first
cutpoint of 10,650 occurs.
6.1.3 Cost Distributions among Organ Diseases
The previous analysis indicates that diabetes has many complications such as
heart disease or renal failure. We will demonstrate the expenditures on these organ
diseases shown in Figure 6.4. Before that, we need to generate a new variable, ORGAN
with the following SAS code:
DATA SASUSER.IPORGAN (KEEP=CLM_CD CLM_TOTO_CHRG_AMT
DIAGNOSES HEA KID OCULO NEU); SET SASUSER.IPCLAIMDEMO;
HEA=Oi KID=Oi OCULO=Oi NEU=O;

DIAGNOSES= CAT X ( , , , ICD9_DGNS_CDl, ... ICD9_DGNS_CD16);
IF(RXMATCH('4280',DIAGNOSES»0)THEN HEA=l;
IF (RXMATCH ( , 4254' , DIAGNOSES) >0) THEN HEA=l; ...
DATA SASUSER.ORGAN; SET SASUSER.IPORGAN;
IF HEA=l THEN ORGAN=li IF KID=l THEN ORGAN=2; IF OCULO=l
THEN ORGAN=3i IF NEU=l THEN ORGAN=4i RUN;

The graphs in Figure 6.5 indicate that before the costs reach the value of 9,900
dollars, the cost with heart disease, the cost with ophthalmic diseases and the cost with
neurological disorders have almost the same probability, which is much higher than the
cost without any of the organ diseases; the probability for the cost with kidney disease is
the smallest. However, after the cutpoint at 34,350 dollars, the density of the cost with
kidney disease is higher than any other densities. It shows that kidney disease has the
highest probability of the highest cost while neurological disorders have the highest
probability of lowest cost with heart disease and ophthalmic diseases having similar
probabilities as neurological disorders.
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Figure 6.5. Costs by Different Organ Diseases

6.2 Outcomes Research
6.2.1 Association Rule Analysis of Procedures
Before we study the outcomes of inpatients, we conduct market basket analysis of
various procedures and the results are displayed below. Figure 6.6 shows all the major
connections between different procedures. The procedures shown in table 6.2 are
important, since all of the rectangular boxes representing those procedures are bigger
than the others. Among the procedures, five of them are used for cardiac di sease and one
is related to hematic disease, which form 6 centers of the diagram; they are marked with
an asterisk, '*' in Table 6.2.
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8856 &8853 &3601
8858 &3607 &36018856&3722 &360t8858 &3722 &3607

Figure 6.6. Associations of Procedures

Table 6.2 Translations for Important Procedures
Code

3601*
3607*
3722*
3772
3783
3893
3895
3995
4516
4523

Procedure
Single vessel percutaneous translurninal coronary angioplasty
Insertion of drug-eluting coronary artery stent(s)
Left heart cardiac catheterization
Initial insertion of tran svenous leads [electrodes] into atrium and
Initial insertion of dual-chamber device
Venou s catheterization, not elsewhere classified
Venous catheterization for renal dialysis
Hemodialysis
Esophagogastroduodenoscopy [EGD] with closed biopsy
Colonoscopy
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Code
8853*
8856*
9339
9383
9604
9671
9672
9904
9920

Procedure
Angiocardiography of left heart structures
Coronary arteriography using two catheters
Other physical therapy
Occupational therapy
Insertion of endotracheal tube
Continuous invasive mechanical ventilation for less than 96 consecutive
Continuous invasive mechanical ventilation for 96 consecutive hours or
Transfusion of packed cells
Injection or infusion of platelet inhibitor

Table 6.3 Confidence and Lift for Rules
Rules

Confidence

Lift

(%)

Initial insertion ... atrium and ventricle==> Initial insertion of dual-chamber device

100

73.22

Initial insertion of dual-chamber device==> Initial insertion ... atrium and ventricle

97.28

73.22

Angiocardiography of left heart structures ==> Coronary arteriography

94.17

9.38

Angiocardiography of left heart structures==> Left heart cardiac catheterization

89.92
89.24

8.96
9.56

Coronary arteriography==> Left heart cardiac catheterization

83.64

8.96

Hem dialysis== > Venous catheterization for renal dialysis

79.61

7.41

Insertion of drug-eluting coronary artery stent(s)==> Single ... coronary angioplasty

78.68

18.37

Left heart cardiac catheterization==> Angiocardiography

78.66

9.56

Coronary arteriography==> Angiocardiography of left heart structures

77.21

9.38

Insertion of drug-eluting coronary artery stent(s)==> Coronary arteriography

77.16

7.08

Occupational therapy==> Other physical therapy

77.08

43.06

Other physical therapy==> Occupational therapy

76.29

43.06

74.27

14.74

73.27

7.28

72.84

7.26

71.07

7.61

68.10

7.29

66.81

18.37

64.36

6.89

63.25

12.55

56.04

14.74

Left heart cardiac catheterization==> Coronary arteriography

Continuous invasive mechanical ventilation==> Colonoscopy
Injection or infusion==> Coronary arteriography
Single ... coronary angioplasty==> Coronary arteriography
Insertion of drug-eluting coronary artery stent(s)==> Left heart cardiac
catheterization
Single ... coronary angioplasty==> Left heart cardiac catheterization
Single ... coronary angioplasty==> Insertion of drug-eluting coronary artery stent(s)
Injection or infusion==> Left heart cardiac catheterization
Continuous invasive mechanical ventilation more than 96 hour==> Insertion of
endotracheal tube
Continuous invasive mechanical ventilation more than 96 hour==>Continuous
invasive mechanical ventilation
Single ... coronary angioplasty==> Angiocardiography of left heart structures
Insertion of drug-eluting coronary artery stent(s)==> Angiocardiography
Insertion of endotracheal tube==> Continuous invasive mechanical ventilation more
than 96 hour
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55.60

6.75

55.33

6.72

38.46

12.55

Table 6.3 just shows the important and meaningful rules; the combination cases
are not considered. The initial insertion of trans venous leads [electrodes 1into the atrium
and ventricle will be used given that the procedure, initial insertion of dual-chamber
device will be subsequently used. The lift value for this rule is 73.22, which indicates that
the association between these two separate procedures is strong. For the same reason, the
relationship between occupational therapy and other physical therapy is also strong. The
confidence values are higher for the other rules in the table, which indicate that it is very
likely that subsequent procedures will be used if the antecedent procedure is used, since
all the left confident values are high.

6.2.2 Mortality Prediction of Diabetes Inpatients
One of dominant issues in outcomes research is about mortality. In this section,
we use various kinds of supervised learning approaches shown in Figure 6.7 with
mortality as the targeted variable; Age, Gender, Diagnosis Procedures and Diagnosis
Procedures are identified as the input variables. To predict mortality, we use the
regression model, the Dmine Regression model, the Neural Network model, the Auto
Neural model, the Decision Tree model, the MBR model, the Rule Induction model and
the Model Comparison model; and these nodes are shown in Figure 6.7. Table 6.4 shows
that the Model Comparison node identifies the decision tree as the optimal model based
on misclassification rates.
The ROC maps in Figure 6.8 show that for all three data subsets: Train, Validate
and Test, there are no big differences in accuracy among the various models. According
to the lift curves, we can find the patients at highest risk of dying. Figure 6.9
demonstrates that except for the MBR node, there are no differences among the other
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nodes in terms of the prediction of mortality. In the train set, validate set and test set,
40 % of beneficiary records have a higher level of prediction than just chance.
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Figure 6.7. Predictive Models Diagram

Table 6.4 Fit Statistics of the Comparison Model Targeting at Mortality
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Table 6.5 Variable Importance in Tree Targeting at Mortality
NAME

IMPORTANCE

VIMPORTANCE

RATIO

PROCLUSTER
DIACLUSTER
Age
Utili zation Day Count
Total Charge

1.0000
0.7254
0.3845
0.3364
0.2466

1.0000
0.6807
0.3993
0.3464
0.2528

1.0000
0.9384
1.0386
1.0297
1.0252
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Results in Table 6.5 demonstrate that the order of importance in the levels is
procedures> diagnoses >age > days of staying in the hospital> total charges. The tree
diagram in Figure 6.10 displays how the input variables affect mortality; the first segment
is divided on the procedure cluster, indicating that procedures are essential to mortality;
the next split is based upon the diagnosis cluster. The followin g split criteria vary from
the left side to the right side. Age has no relation to mortality related to the procedure
cluster #5 (endotracheal tube and catheteri zation) and #7 (Some heart operations); for the
procedure cluster 1 and cluster3 , age is also an important factor. Before the age of 82.5 ,
both total charges and utilization day count should be considered, while after th at, only
utilization day count should be focu sed on .
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Figure 6.10. Tree Di agram Aiming at Mortality
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6.3 Readmission Analysis
Under the current economic circumstances, medical care providers have become
concerned about readmission rates. In this section, we attempt to find the diabetes
patients who have higher risks of readmission using Medicare inpatient claims data from
the CMS CCW data [18]. We first introduce the definition of readmission by CMS; then,
we use SAS SQL to get the inpatients who re-enter the hospital after discharge within 30
days and the most frequent diseases and procedures for these patients; before we perform
supervised learning, we conduct pattern recognition analysis.

6.3.1 Medicare Readmission
When defining readmission, different researchers give different definitions. CMS
defines readmission as the re-entry to the hospital after discharge within 30 days and
considers it as an important measure of poor quality health care. One report from the
Atlantic Information Services, Inc. [60] demonstrates that almost 18 % of Medicare
patients are readmitted within 30 days of discharge and 13% of the readmissions ($12
billion worth) can be avoided if the correct treatments are provided. Medical providers
are currently facing pressure to reduce the readmission rate while improving care quality.

It is with this motivation that we evaluate the readmission risk of diabetic patients. We
study three kinds of risk factors influencing readmission rates, (1) patient demographic
information including age, gender, and race; (2) patient disease characteristics such as
common co-morbidities and procedures for diabetes; (3) medical resources usage such as
length of hospitalization and discharge locations.

6.3.2 Data Processing to Find Readmission Inpatients

In the process of conditionally inner joining the two tables, observations are
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grouped by patient ID and dates; each group having the property that the differences
between the discharge date and the readmission date is less than 30 days. The code is:
PRoe SQL; CREATE TABLE SASUSER . AD AS

SELECT Tl .BE NE_ID , Tl . CLM_ADMSN_DT ,T l . NCH_BENE_DSCHRG_DT ,
DATDIF(Tl . NCH_BENE_DS CHRG_DT , MIN(T2 . CLM_ADMSN_DT) , ' ACT/ACT ')
AS DATEDIF , MIN (T2 . CLM_ ADMSN_DT) FORMAT=DATE9 . AS MINAD
FROM SASUSER . QRDM2010 AS T1
INNER JOIN SASUSER . QRDM2010 AS T2
ON Tl . BENE ID=T2 . BENE 10 AND
Tl . CLM_ADMSN_DT<T 2 . CLM_ ADMSN_DT AND
T2 . CLM_ADMSN_DT>Tl . NCH_BENE DSCHRG_DT

WHERE Tl . NCH_BENE DSCHRG_DT IS NOT NULL AND Tl . CLM_ADMSN_DT
IS NOT NULL GROUP BY
Tl . BENE_ID , Tl . CLM_ADMSN_DT , Tl.NCH_BENE_DSCHRG_DT
HAVING DATDIF (T l .NCH_BENE_DSCHRG_DT, MIN(T2 . CLM_ ADMSN_DT )

, ' ACT/ACT ') <= 30 ORDER BY DATEDIF i QUITi

6.3.3 Pattern Recognition
We first conduct pattern recognition analysis using the cluster node in Enterprise
Miner with the hierarchical clustering algorithm.
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Some results shown in Figures 6.11 - 6.14 gi ve us a rough description of the
inpatients. The patients are segmented by 5 age groups. In Figure 6.11, the x-axis, the yaxis and the z- axis stand for CVD (Cardiovascular Disease), gender and admission
frequency respectively. It is the same for the other graphs. Generally, as Figures 6.116.12 and 6.14 demonstrate, there is no obvious difference in frequency of hospitalization
in different age groups for those patients who have cardiovascular disease or renal
disease or have procedures related to these diseases. However, the patients who have
heart disease are more likely to be admitted to the hospital than those who do not and this
difference can be seen in the axis representing CVD in Figure 6.11. Figure 6.14 indicates
that the male patients who receive heart procedures have a higher possibility of
readmission compared to female patients. When comparing Figures 6.11- 6.12 to Figure
6.13 , we can also conclude that in most cases, the patients with cardiovascular
disease or kidney disease have a higher risk of readmission after discharge compared
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to those with other diseases such as digestive disorder.

6.3.4 Supervised Learning with Readmission as the Target
In the following analysis, we need a more accurate estimate of the readmission
risk; then, we will perform supervised learning. First, we combine the patients who
readmitted to the hospital with the other inpatients and define a new variable, RA for
readmission risk.
Next, we utilize the code displayed below to find out the top 20 most frequent
procedure codes for the patients readmitted and apply a similar method to get the top 20
diagnosis disease codes. The most common co-morbidities are heart disease, kidney
disease, digestive disorder and respiratory disease and the most frequent procedures are
those related to the above diseases. Therefore, we apply the CATX, 0-1 indicator and
RXMATCH functions to define the new predictors such as CVD (Cardiovascular disease)
and PKD (Procedures related to kidney diseases) with the SAS code:

/*put all procedures into one column*/
PROC SQL;CREATE TABLE SASUSER.PR004 AS
SELECT BENE_ID, ICD9_PRCDR_CDl AS PRO FROM SASUSER.RD04
WHERE ICD9_PRCDR_CDl IS NOT NULL

UNION

SELECT BENE_ID, ICD9_PRCDR_CD2 AS PRO FROM SASUSR.RD04
WHERE ICD9 PRCDR_CD2 IS NOT NULL ...
/*find the freq of procedures*/
CREATE TABLE SASUSER.COUNT AS
SELECT PRO, COUNT(*) AS C FROM SASUSER.PR004

GROUP BY PRO

ORDER BY C DESCEDING; QUIT;

For a precise prediction, we utilize the variable selection node in SAS Enterprise
Miner 6.2 to select the prominent input variables by R2 shown in Figure 6.15.
Considering the large data sample, we choose the variables with R2 greater than 0.1 and
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they are patient discharge location, Medicare status, diabetes, kidney disease, length of
stay in the hospital, respiratory disease and procedures related to kidney dysfunctions.
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Figure 6.15. Selected Variables by R-square

Figure 6.16. Various Predictive Models

Now, we can use different models such as the decision tree models (with the
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default method or with the CHArD algorithm), the logistic regression model and the
neural network model to predict readmission risk. Figure 6.16 shows the process flow.

Table 6.6 Important Variables to Readmission Estimation
Number of splitting rules

Importance

Medciare status

2

0.74

Diabetes

3

0.48

Variable name
Discharge places

Length of hospitalization

0.41

Kidney disease

0.33

Respiratory di sease

0.22

o

o

Procedures related to kidney diseases

&1.51..

I

Di scharge place code 0 I :home; 02: short term general hospital ; 03:skilled nursing facility; 06:home
health service; 30: still patient; 51 hospice - certified medical facility ;62: inpatient rehab facility;
63:Medicare certified long term care hospital.

Figure 6.17. Tree Diagram with CHAID for Readmission
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The model comparison node chooses the decision model with the CHAID
algorithm as the optimal model. The outputs shown in Table 6.6 demonstrate that patient
discharge places, patient status (old or old with end stage renal failure), LOS (length of
stay in the hospital), kidney disease and respiratory disease are key factors to predict
readmission rate. In the above tree diagram (shown in Figure 6.17), such organizations as
a short term hospital, a skilled nursing facility and a Medicare-certified long term care
hospital can provide professional medical services while the other organizations do
not. The diagram indicates that the inpatients who are discharged to home or hospice
have a higher readmission rate than other patients.

6.4 Two - way Interaction Effects of Diabetes Complications
In the previous sections, we discussed the key factors to costs and outcomes
without considering the interactions between each factor. In this section, we will analyze
the two-way interaction effects of diabetes complications such as cardiovascular disease
and hypertension on Medicare expenditures and health outcomes such as frequency and
length of hospitalization. For two factors, A and B, two - way interaction effect analysis
reflects whether a level of effect of factor A is influenced by a level of effect of factor B.
An interaction plot can simply and vividly demonstrate the interaction, but in most cases,
these interactions need statistical demonstration.

6.4.1 Data Processing
In order to get the data ready for our analysis, we process the data in the following
steps.
•

Conditionally inner join the two data sets, inpatient claims data and beneficiary
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demography data by beneficiary ID.
•

Use random sampling to reduce the data size from 244,299 records to 40,000
claims.

•

Use the proc means procedure to get the average costs, average days in the
hospital and total times of entering the hospital for each beneficiary ID (Each
patient in Medicare has hislher own unique beneficiary ID).

•

Utilize the CATX function, RXMA TCH function and 0-1 indicator functions to
generate binary variables, common diabetes complications and they are Hea
(Heart disease), Kid (Kidney disease), Eye (Eye disease), Neu (Neurologic
disease) and Hyper (Hypertension).

•

When we develop the logistic regression model to predict mortality, we apply
overs ample to guarantee that all the observations of mortality are included in the
sample and we use the following SAS code:
PROC SORT DATA=SASUSER.INTERACTIONNEW OUT=SASUSER.LOGISTIC;
BY STATUS; RUN;
PROC SURVEYSELECT DATA=SASUSER.LOGISTIC
OUT=SASUSER.OVERSAMPLE
SEED = 39585784

SAMPSIZE = 1256;

STRATA STATUS; RUN;

Now we get what we want and we can perform our analysis in the following
sections.
6.4.2 Two - way Interaction Effects of Diabetes Complications on Cost
We start our study with cost analysis. In order to examine whether there exist
significant two-way interaction effects between diabetes complications, we firstly plot
interaction effects on Medicare payments. We use the following SAS code and the

lO4

similar codes for the other interaction effects plots .The variables are explained in
Table 6.7.
PRoe SORT DATA=SASUSER.INTERACTIONNEW OUT=SASUSER.NEW1;

BY HEA_MAX HYPER_MAX; RUN;
PROe MEANS DATA=SASUSER.NEW1;
VAR CLM_PMT_AMT_MEAN; BY HEA_MAX

HYPER_MAX;

OUTPUT OUT=SASUSER.NEW2 MEAN=CLM_PMT_AMT_MEAN;RUN;
SYMBOL VALUE=DOT I=JOIN;PROe GPLOT DATA=SASUSER.NEW2;

PLOT CLM_PMT_AMT_MEAN * HEA_MAX = HYPER_MAX; RUN;

Table 6.7 Explanations for Variables
Explanation

Variable

A verage payments for each patient

CLM]MT_AMT_MEAN
HEA_MAX

Heart disease

HYPER_MAX

Hypertension

OCULO_MAX

Eye disease

NEU_MAX

Neurological disease

An interaction effect plot gives a general estimation whether an interaction effect
is significant and how the two different factors influence each other. The rule [611 is that
if the two lines (representing the two levels of one factor) do not cross and are not
parallel to each other, then the effect is significant. The difference of two levels of one
factor indicates the main effect of the other factor. If the two lines interact with each
other, the interaction effect is still significant, but the main effect should not be
considered.
To be specific, let us look at the plots in Figure 6.18. These plots demonstrate
some interactions between different diseases with Medicare payments as a response
variable and they are significant according to the stated rule. Consider kidney disease, for
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example; its interaction effect with a neurological disorder is significant and for diabetes
inpatients with kidney disease, there is a big difference on their costs between the case
when they have a neurological disorder and the case when they do not.
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Figure 6.18. Interaction Effects on Costs Plots
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However, the above plots just provide a basic idea; we need to use statistical
models to further prove the significance of the interaction effects. We input the variables
listed in Table 6.7 and their two-way interaction as predictors into the generalized linear
model with a gamma distribution and use Medicare payments as the response variable,
then we get the type III analysis results shown in Table 6.8. The table shows that without
considering main effects, only these interaction effects are significant in the model of
Medicare payments and they are: interaction between heart disease and kidney disease,
interaction between heart disease and hypertension, interaction between kidney disease
and neurological disease, interaction between kidney disease and hypertension,
interaction between eye disease and neurological disease, and interaction between eye
disease and hypertension since all of their p-values are smaller than the significance level
0.05.
Table 6.8 Type 3 Analysis for Interaction Effects(Cost)
Wald Statistics For Type 3 Analysis
Source

DF; Chi·Square

Pr> ChiSq

Hea_Max*Kid_Max

1

22.64

<.0001

Hea_Max*hyper_Max

1 iI

25.86

<.0001

Kid_Max*Neu_Max

11

17.96

<.0001

Kid_Max*hyper_Max

1!

10.66

0.0011

Oculo_Max*Neu_Max

1

7.76

r--

Oculo_Max*hyper_Max

"~~-------

I.

12.11

c---

0.0053
------

~~

~-

0.0005

6.4.3 Two - way Interaction Effects on Length of Hospitalization
In this section, we discuss the influence on length of stay (LOS) in the hospital.
From this section on, we will directly investigate the effects with statistical models
without demonstrating interaction plots. Because LOS also follows a gamma distribution
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and has similar properties to Medicare payments, we use the generalized model with a
gamma distribution. Table 6.9 displays the significant interaction effects. It demonstrates
that for patients with other complications, the fact that they have kidney disease or not
makes their LOS different. This conclusion is also true for hypertension.

Table 6.9 Type 3 Analysis for Interaction Effects (LOS)
LR Statistics For Type 3 Analysis
Source

DF

Chi-Square

Pr> ChiSq

Hea_~ax*hyper-~ax

1

38.37

<.0001

Kid_~ax*Oculo_~ax

1

3.99

0.0458

Kid_~ax*Neu_~ax

1
---

11.03
f------

0.0009
-----~---

Kid_~ax*hyper-~ax

1

3.88

0.0487

Neu_~ax*hyper-~ax

1

8.40

0.0038

Oculo_~ax*hyper_~ax

1

10.55

0.0012

6.4.4 Two - way Interaction Effects on Frequency of Hospitalization
In this section we will discuss the interaction effects on frequency of
hospitalization, i.e., the average times of hospital stay for each patient. Since the
frequency is a count variable, we assume that it follows a Poisson distribution. Therefore,
we apply a Poisson regression model for our analysis. In order to adjust the over-fitting of
this model, we set "scale = Pearson" and the SAS code is shown below.
PROC GENMOD DATA=SASUSER.INTERACTIONNEW;
CLASS

Hea~Max

MODEL COUNT=

Kid~Max

Oculo~Max

Hea~Max*Kid~Max

...

Neu~Max

hyper~Max;

hyper~Max/

LINK=LOG
DIST=POISSON
SCALE=PEARSON
TYPE3;
LSMEANS

Hea~Max*Kid~Max

... / ALPHA=O. 05; RUN;
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The scaled deviance and the scaled Pearson X2 (Table 6.10) indicates that the
model fit the data relatively well. Table 6.11 (Only significant interaction effects left in
this table) demonstrates that for the patients with other diseases, there is a big difference
in the frequency of being admitted to the hospital between the patients who have heart
disease and those who do not.
Table 6.10 Goodness Fit of Poisson Regression model
Criteria For Assessing Goodness Of Fit
Criterion

DF

Value

Deviance

34E3

4517.0538

ValuelDF
0.1327
- -

~-

Scaled Deviance

34E3

26557.3993

0.7803

Pearson Chi-Square

34E3

5788.5522

0.1701

Scaled Pearson X2

34E3

34033.0000

1.0000

Table 6.11 Type 3 Analysis for Interaction Effects (Frequency)
LR Statistics For Type 3 Analysis
Source

NumDF

DenDF

F Value

Hea_Max*Kid_Max

I

34033

34.45
I

Pr>F

Chi-Square

Pr> ChiSq

<.0001

34.45

<.0001

0.0052

7.79

0.0052

Hea_Max*Oculo_Max

I

34033

7.79

Hea_Max*Neu_Max

I

34033

6.99

0.0082

6.99

0.0082

Hea_Max*hyper_Max

I

34033

50.57

<.0001

50.57

<.0001

Kid_Max*Neu_Max

I

34033

24.67

<.0001

24.67

<.0001

<.0001

121.91

<.0001

Kid_Max*hyper_Max

I

,
I

34033

121.91

i

6.4.5 Two - way Interaction Effects on Mortality
In the last section of two-way interaction effects, we will analyze the effects on
the mortality of inpatients with diabetes. Mortality is a rare occurrence event because the
patients who are dead only account for 4.5% in the whole inpatient population. Hence, in
order to get an objective result, we need to overs ample those patients. We stratify
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STATUS into two classes, dead or alive; then, we sort the data by STATUS and perform
stratified sampling, setting sample size to be 1256 (the total number of the deaths in a
sample with a size of 40,000 claims) and selecting the same number of patients alive. The
code is shown below.
PROC SORT DATA=SASUSER.INTERACTIONNEW OUT=SASUSER.LOGISTIC;
BY STATUS; RUN;
PROC SURVEYSELECT DATA=SASUSER.LOGISTIC
OUT=SASUSER.OVERSAMPLE
SEED = 39585784

= 1256;

SAMPSIZE

STRATA STATUS; RUN;

Once we get the data ready, we perform logistic regression analysis with the
binary variable, STATUS as the dependent variable and the stepwise selection method to
choose the best model. The selection process only proceeds to the second step and then
stops, since no effect in the model can be removed and no additional new effect meets the
requirement of entering the model. The R-square of this model is 13 %; considering the
large data size, it is a reasonable fit, but it still means that 87% of the variability in the
outcome variable remains unaccounted for. Table 6.13 demonstrates that the two -way
interaction effects between heart disease and kidney disease or the interaction effects
between neurological disease and hypertension are significant in the model.
Table 6.12 R-square for Logistic Regression Model

Table 6.13 Type 3 Analysis for Interaction Effects (Mortality)
Type 3 Analysis of Effects

Effect

DF

Wald
Chi-Square

Pr> ChiSq

Hea_Max*Kid_Max

I

14.9807

0.0001

Neu_Max*hyper_Max

I

7.9346

0.0048
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6.5 Conclusion
Cost analysis of inpatients shows that many organ diseases and neurological
disorders indeed have decisive effects on the costs of inpatients with diabetes: heart
disease, eye disease and nervous system diseases raise the inpatients costs. The results
demonstrate that under a threshold amount of costs, kidney disease does not impact the
expenditures of inpatients as much as the other organ diseases do; however, as the costs
increase, the effects of kidney disease become more and more important. Hence, all
inpatients with diabetes should pay more attention to kidney disease, and use prevention
to avoid such diseases to decrease the costs.
Outcomes research demonstrates that among the various procedures, the ones
utilized for cardiac disease treatments are related to many different procedures.
Association analysis also shows that hemodialysis is strongly related to venous
catheterization for renal dialysis. Another discovery is that the procedures and the
diagnoses are decisive to predicting mortality, which is contrary to widely held belief.
Through this readmission study, we can conclude that the following kinds of the
Medicare diabetic inpatients have a high risk of readmission, those who have
cardiovascular disease, kidney disease or those male patients who receive procedures
related to heart disease or those who do not get professional medical care after discharge.
Therefore, in order to decrease readmission risk, we should take greater care of these
kinds of patients. This care might need to include a higher level of reimbursement from
Medicare.
Two-way interaction effect analysis is carried out to study the interaction effects
between various diabetes complications on Medicare payments, length and frequency of
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hospitalization and mortality. Results show that the most interaction effects are
significant to costs, while only the interaction between heart disease and other diseases
are significant to the frequency of hospitalization. Another discovery is that kidney
disease or hypertension has an important influence on the other complications as for
length of stay in the hospital. We also find that the interaction between heart disease and
kidney disease has a decisive effect on mortality.
We have finished studying outpatients and inpatients, and we will investigate the
influence of Medicare, Part 0 on diabetes medications in chapter VII.
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CHAPTER VII
INFLUENCES OF MEDICARE, PART D
Medicare, Part 0 is the optional prescription drug program. It uses competing
private plans to provide beneficiaries access to appropriate drug therapies. In the recently
approved healthcare law, the provisions about this plan were also amended. In this
chapter, we will estimate the influences of Medicare, Part 0 since its implementation in
2006 on diabetes medications from usage and cost-effectiveness perspectives as well as
on diabetes beneficiaries' health status. Our analyses are based on the MEPS data [19],
which cover information about physician visits, inpatients, prescription drugs and
demographic information for the year 2005 and the year 2006. The chapter is organized
as follows: first, the theories related to survival analysis and cost-effective analysis are
introduced, then the impacts of Medicare, part 0 on the usage of diabetes medications are
addressed; finally the influences on the cost-effectiveness of the drugs are presented.

7.1 Basic Theories and Concepts
7.1.1 Survival Analysis
Survival analysis [62] is applied to study the occurrence and timing of events
using statistical methods. It is very useful in studying the events in social and natural
sciences, such as the onset of disease, births and death. In our research, we will utilize
survival analysis to find the first switch of medication.
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1. Censoring

Censoring is an important element in survival analysis, which distinguishes this
analysis from other statistical methods. Censoring can be counted as an incomplete
observations issue and it has three forms: left censoring, right censoring and interval
censoring and two types: type I censoring, type II censoring and random censoring as
follows:
•

Left Censoring: An observation on a variable T is said to be left censored if Tis
only known when it is smaller than a value

•

Right Censoring: An observation on a variable T is said to be right censored if Tis
only known when it is greater than a value

•

fl.

f2.

Interval Censoring: An observation on a variable T is said to be interval censored
if T is known when it belongs to the interval [f/,

t2].

•

Type I censoring occurs when the values

•

Type II censoring occurs when observation is terminated after a pre-specified

fl. t2

are fixed.

number of events have occurred.
•

Random censoring occurs when the time of censoring and the survi val
time are independent.
In our research, we employ left censoring and type I censoring to study drug

usage. We set the end of one year as the censored time; and if some drug user does not
switch the drug to another, then the drug is said to be left censored.

2. Descriptions
In this part, we discuss the two standard approaches of describing survival
analysis: (l) survival function, (2) hazard function.
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(1) Survival Function: It is defined as the probability that an individual survives longer

than t,
s(t) = peT > t) = 1- F(t)

in which F(t) is a cumulative distribution function of variable

(7.1)
I.

If the event of interest is

a medicine switch, then the survivor function gives the probability that the drug remains
to be used beyond time t.
(2) Hazard Function: If a variable under survival analysis is continuous, then the hazard
function is preferred and it is defined as:
p(t ::; T ::; t + ~tlT ~ t)

h(t)

= lim-------'--~t

ru-.o

(7.2)

The importance of this function lies in its interpretations. If the occurrence of an event
can be repeatable, then the hazard gives an idea about the number of events per interval
of time. For a non-repeatable event such as death, its reciprocal tells how much time is
left before the event occurs.

3. Estimation of Survival Functions
The estimation of survival functions is a traditional approach including the KM
(Kaplan- Meier) method and the life table method. Due to the large data set, we prefer the
latter method, in which the survival estimate is obtained by calculating the conditional
probabilities of surviving beyond time t, defined by
i-I

;-1

Set) =nO-qj) =nPj
j=1

(7.3)

j=1

For each time interval i, I; is the start time, qi is the conditional probability of failure and
Pi is the conditional probability of surviving to Ii or beyond that time.
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7.1.2 Cost Effectiveness Analysis
Policy makers want to spend fewer dollars while achieving greater treatment
effects. Cost effectiveness analysis, a newly-emerged method in health economics or
pharmacoeconomics, can help those people realize their goals. In this section, we will
briefly introduce the essential concepts, theories and methods used in this methodology.
1. Basic Concepts

Before discussing the theories, several concepts [63, 64] should be considered.
•

Health Intervention: This can refer to a treatment, test, or primary prevention
technique, which is used to improve patients' health status or decrease mortality.

•

Health Status: If we define a specific state of health, for instance, reducing pains,
as a health state, then a health status is the sum of health states. Typically, there
are six levels, from pretty healthy to dead shown in Table 7.1.

•

QALY (Quality-Adjusted Life Year): It is a measure to estimate quantity and
quality of life generated by healthcare interventions. QALY can be calculated as
follows:
QALY = Weight of Health Status

* Life Expectanc.v

(7.4)

In the above equation, weight of health status is defined by researchers. We
define these weights in Table 7.1. Life expectancy is how many years left for a
person before s/he dies and it can be looked up in a life table [65].
•

ICER (Incremental Cost Effectiveness Ratio): It is the most frequently-used and
most important element in health economics, which distinguishes it from other
kinds of economics. It is typically defined as a ratio of difference in costs to
differences in effects of interventions, shown in (7.5).
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ICER= (cost new

-

coStold) / (effectnew - effectold)

(7.5)

leER indicates the additional costs required to generate one unit of effect. The
effect is usually measured by QALY, and the cost is measured in currencies.
leER is used to compare two treatments or two drugs on the same patients in
clinical trials, but we apply it to compare two cases for the two years for the same
drug treatment with the same patients.
Table 7.1 Weights of Health Status

Level of Health Status

Weight

Pretty Healthy
Healthy

0.8

Relatively Healthy

0.6

III

0.4

Severely III

0.2

Dead

o

2. Common Methodologies
In cost effectiveness analysis, two kinds of models [661 are often utilized. One is
the decision tree model, different from what we discussed in the previous chapters. The
tree model must first be split on two interventions, and then each intervention node is
split into several sub-trees about costs and outcomes with corresponding probabilities.
The other is a Markov model, assuming that there are finite numbers of defined health
states, and at any time, each patient should be assigned to one health state. At the end of
each state, the patients can be shifted from one state to another state with a certain
probability. Another approach is one-way sensitivity analysis [67] , in which one variable
is chosen to change values and the other variables are kept constant each time; the leER
are calculated to see whether the parameter is sensitive or not.
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3. Our Approach
In part 2, we introduced several common methods; however, they are not suitable
for our studies. Instead, we apply medical resources usage analysis.
In the following section 7.2, we will investigate the impacts on diabetes
medications using survival analysis; in section 7.3, we will examine the effects on the
cost effectiveness of drugs and patient health.

7.2 Impacts of Medicare, part D on the Usage of Diabetes Medications
In this section, apart from survival analysis, we also perform summary statistics
and kernel density estimation to understand the impacts better.

7.2.1 Summary Statistics
We use Summary Statistics to get the average Medicare payment and the average
total payment. For comparison, the average Medicare payment in 2005 is expressed in
2006 dollars with 2005 data inflated based on the CPI-U (Consumer Price Index for all
Urban Consumers) for prescription drugs [68]. That is to say, once we get the mean
values for the year 2005, we mUltiply them by the index 1.043. To demonstrate this
conversion, we put an asterix on the right upper comer of '2005' in Table 7.2.

Table 7.2 Average Overall Payment and Medicare Payment in 2005 & 2006
Year

Variable

Mean

N

2005*

SUM OF PAYMENTS
MEDICARE (IMPUTED)

501.66
20.58

1759
1759

SUM OF PAYMENTS

558.11

MEDICARE (IMPUTED)

129.02

1994
1994

2006
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05 Average Diabetes Medic ation s
Expectation

06 Average Diabetes Medications
Expenditure s

Figure 7.1. Pie Charts of Payments in 2005 &2006

Table 7.2 and Figure 7.1 show that the average of total payments for the
prescription increases approximately 12 % from the year 2005 to the year 2006, while the
average Medicare payment in 2006 is 6 times as much as that in 2005 . The ratio of the
average Medicare payment to the total expenditures also increases from 4 % to 23 %.
Results demonstrate that the plan, Part D, indeed increases Medicare drug expenditures.

7.2.2 Kernel Density Estimation among Diffe rent Clusters of Drugs
Next, we want to see how Medicare payments are distributed among different
groups of drugs. We compare Medicare payments in two cases , the general case and the
Medicare case in which the beneficiaries join Medicare. We need to preprocess the data
sets. First, we convert the variable, NRXNAME, into observations by the transpose
procedure, the trim function, the translate function and the concatenation operator. The
SAS code [26] is shown below.
PROC SORT DATA=SASUSER.SMED06 OUT=SASUS ER . SORTMED06 ;
BY DUPERSID NRXNAME; RUN; OPTIONS OBS=MAX ;
DATA SASUSER. SORTMR06 ; SET SASUS ER . SORTMED06 ;
NRXNAME= TRANSLATE (LEFT (TRIM (NRXNAME) ), '_','

' ) ; RUN ;

PROC TRANSPOSE DATA=SASUSER . SORTMR06 OUT=SASUSER . TRANMR06
PRE F IX=MED_ ; VAR NRXNAME; BY DUPERSID ; RUN ;
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DATA SASUSER . CONMR06

(KEE P= DUPE RS1D SSNRXNAME) ;

LEN GTH SS NRXNAME $ 32767 ; SET SASUS ER . TRANMR 06 ;
ARRAY CONCAT MED_ :; SS NRXNAME =L EFT(TR1M(MED_l )) ;
DO 1= 2 TO D1 M( CONCAT) ; SSNRXNAME =LEFT( TR1M ( SSNRXNAME))
I I I I LEFT (TRIM (CONCAT[1] )) ; EN D; RUN;
I

I

(1) General Case:
After we get the clusters shown in Figures 7.2 & 7.3 using SAS Text Miner, each
cluster is explained in Tables 7.3 & 7.4; we can do kernel density estimation on Medicare
payments by clusters .

.Clusters

[O[

l ~ [ Percentage

Descri~ive Terms

l[ RMS std. 1

'1 glyburide,rosigl~azone , precose,metformin,glyburide·metformin

271 0.154328018 ... 0.07"11406 ...

2 glyburide·metformit\ +supply I ~arlix, precose,prandin

493 0.280751708... 0.1198462 ...

3 insulin I piogl~azone, +supply I ~arlix , prandin

237 0.134965831... 0.0374267 . .

4 metformin ,glimepiride,tolazamide,prandin ,rosigl~azone

494 0.281 321'184.. . 0.0838507...

5 glipizide I rosigl~azone I precoseI siarli xI metforrnin

261 0:148633257.. . 0.0693840 ...

Figure7.2. Clusters of Drugs in 2005
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·Clusters

[O[

)~ [ Percentage )[ RMS std.

Descriptive Terms

1 glyburide·mejlormin glimepiride starlix insulin prandin

214 0:10896'1303 ... 0.2865909 ...

2 +supply glirnepiride

358 0.182281 059 ... 0.0148972 ...

I

I

I

I

I

3 glyburide rosiglrrazone precose glyburide·melformin melformin

272 0.1 3849287'1... 0.0554535 ...

4 insulin +supply starlix,precose,glyburide·melformin

228 0.1'1608961 3... 0.0484771...

5 tolazamide,metformin,glimepiride,prandin,precose

61 '1 0.311 099796 ... 0.0897675 ...

6 glipizide rosiglrrazone pioglrrazone precose melformin

28'1 0.143075356 ... 0.0510506 ...

I

I

I

I

I

I

I

I

I

I

Figure 7.3. Clusters of Drugs in 2006

Table7.3 Explanation for Clusters in 2005
Cluster #

Label
Metformin , Glyburide and their combination

2

Supplies

3

Insulin, Supplies

4

Metformin, Glimepiride

5

Metformin, Glipizide

Table 7.4 Explanation for Clusters in 2006
Cluster#

Label
Insulin , Glyburide-metforrnin

2

Supplies

3

Glyburide, metformin and their combination

4

Insulin , Supplies

5

Metformin , Glimepiride

6

Metformin , Glipizide
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Figure 7.4. Kernel Density Estimation for Medicare in 2005

Male:

Female:

Density
0005

Density
0005

0004

0004

0003

0003

0002

0002

0001

0001

0000

\

0000
100

200
300
Medicare06

400

500
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200
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Figure 7.5. Kernel Density Estimation for Medicare in 2006

Figure 7.4 demonstrates that most Medicare payments for diabetes medication
are fewer than 200 dollars. For males, most costs of the drugs are lower than 50 dollars.
The only exception is cluster 1, which indicates that Medicare pays more for metformin
and glyburide, and their combination. For female patients, the densities of clusters #2 and
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#4 are higher than those of the other clusters under 50 dollars; after that, the density of
cluster 3 is the highest. Hence, female patients spend more on insulin and supplies. In
2006, the ordering for males' expenditures is cluster# 2 > #5> #6>#1>#3 under 120
dollars; after the threshold point, the densities for clusters #1 and #3 become higher than
the others. Women spend much more on clusters #2 and # 5 of the drugs under 140
dollars, indicating that metformin and supplies cost females more than the others do.
Hence, most Medicare expenditures are on supplies, metformin and glyburide.
(2) Medicare Case
Figures 7.6 and 7.7 show that in 2006, with the Part D introduction into Medicare,
the expenditures on drugs are greatly increased. The costs of the diabetes supplies,
metformin and insulin remain higher than the other costs.

Female:

Male:
Density
00025 . - - - - - - - - - - - - - - - - - - ,

Density
00030

00020

00025
00020

0.001 5
00015
00010
00010
0.0005

0.0005

0.0000 ' r - - - - , - - - , - - - - , . - - . - - - - . , - - - - - , J
200
400
BOO
1000
1200
600
Calculation 1

00000
200

Cluster 10 -2 - 3

400

BOO
600
Calculation 1

Cluster 10 -2 - 3

Figure 7.6. Kernel Density Estimation of 2005 Medicare
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Figure 7.7. Kernel Density Estimation of 2006 Medicare

7.2.3 Association Analysis
In this section, we use the association node in EM 5.2 to get the link graphs for
relationship analysis of diabetes oral medications. In each graph, each square stands for a
drug; those drugs which are connected to many different drugs form centers and are
important in diabetes treatment. The link graphs are displayed in Figures 7.8-7.11.

'\i""LI~H'UUH

Figure 7.8. Link Graphs for the Drugs in 2005 (General Case)
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Figure 7.9. Link Graphs for the Drugs in 2005 (Medicare Case)

Figure 7.10. Link Graphs for the Drugs in 2006 (General Case)

.UPP'UI!!i!I!.. tfe,,,,,n

Figure7.ll. Link Graphs for the Drugs in 2006 (Medicare Case)
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In this analysis, we also discuss the general case and the Medicare case. In 2005
in general case (shown in Figure 7.8), diabetes supplies and metformin were two centers
of the graphs. Insulin has a strong relationship to supplies, although it is not related to the
other factors. Glyburide, and glipizide are also fundamental. When we study the
beneficiaries who get their drugs paid by Medicare (shown in Figure 7.9), metformin
becomes more prominent and it is strongly related to glyburide and glipizide. In 2006, the
general case (displayed in Figure 7.1 0) remains almost the same except that the supplies
are connected to the combination of insulin and metformin. In the Medicare case
(displayed in Figure 7.11), there are fewer connections between different drugs. Figure
7.11 indicates that if insulin is prescribed, then the supplies are very likely to be
prescribed, too. Also, once the combinations of the supplies with glyburide are used, then
metformin will probably be utilized.

7.2.4 Survival Analysis
Finally, we perform survival analysis by the life test procedure. For a better
comparison, we also need physician visit information in 2005. For the year 2006, we
process the missing time information using the following SAS code and then sort out the
records for the year 2006 to get the data set shown in Figure 7.12.
PROC SQL;
CREATE TABLE SASUSER.SMRS06 AS SELECT SRSMED06.DUPERSID,
SRSMED06.RNRXNAME, (( CASE WHEN -1 = SRSMED06.RXBEGDD THEN 1
WHEN -8 = SRSMED06.RXBEGDD THEN 1 WHEN -9 =
SRSMED06.RXBEGDD THEN 1 ELSE SRSMED06.RXBEGDD END)) AS
RXDD,
((CASE WHEN -1 = SRSMED06.RXBEGMM THEN. WHEN -8 =
SRSMED06.RXBEGMM THEN. WHEN -9 = SRSMED06.RXBEGMM THEN.
ELSE SRSMED06.RXBEGMM END)) AS RXMM,
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(( CASE WHEN - 1 = SRSMED06 . RXBEGYRX THEN 2006 WHEN -14 =
SRSMED 06 . RXB EGYRX THEN 2006 WHEN - 7 = SRSMED06 . RXBEGYRX
TH EN 2006 WH EN -8 = SRSMED06 . RXB EGYRX THEN 2006 WHEN -9
SRSMED06 .RXBE GYRX THE N 2006 ELS E SRSMED06 . RXBEGYRX END )) AS
RXYY
FROM SASUSER . SRSMED06 AS SRS ME D06 WHERE CALCULATED RXYY =
2006 i QUIT i

Next, we suppress the data by removi ng the repeated information and the SAS
code is as follows:
PROC SORT DATA=SASUS ER . SMRS06 OUT=SASUS ER . UNISMRS06
NODUPKEYi BY DUP ERSID SSNRXNAMEi RUN i

DUPEASID
1
2
3

..

5
S
7
8
9

10

30078019
3012101 2
3014901 0
30177026
30177026
30180024
..
3019201 2
30206025
30217015
3030001 3

SSNRXNAME

RXDD

RXYY

RXMM

2006
2006
2006
2006
2006
2006
2006
2006
2006
2006

" GLi PIZID E
."

METFORMIN
GLiPIZIDE
. ..
· METFORM IN
· GLYBURIDE
. ...
· METFORMIN
GLi MEPIRIDE
· GLYBURIDE
· METFORMIN

.~.

27
27
..
1.
20:
1
1:
30·

12

.... -....... - ..
.,

.., _.. ,
....

n

~.

'·1·

~

"

2
8:

.... .c.

Figure 7.12. Diabetes Medication in 2006
Next, we convert the date into a SAS date by using the MDY function , transpose
the data by NRXNAME and DATE and finally merge the two new data sets to get the
data displayed in Figure 7.13.
DATU
301 21012
30149010
30177026
30180024
30192012
1 30206025
8 30217015
9 30300013
10 30363015

2
3
4
5
6

DATE
DATE
DATE
DATE
DATE
DATE
DATE
DATE

GLiPIZIDE
METFORMIN
GLiPIZIDE
GLYBURIDE
METFORMIN
GLiMEPIRIDE
GLYBURIDE
METFORMIN
GLiPIZIDE

METFORM IN

17162
16821
16833
17043

Figure 7.13 . Analysis Data in 2006
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17162

Next, we search for the first switching of the drugs and define the variable,
STATUS. During the analysis, we make some assumptions:
•

When we use an array statement, we assume the missing date to be the end of the
year 2006 and also we convert it into a SAS date.

•

If the drug is continued during the survi val time, then it is censored and the value
of STATUS is 0; otherwise, the value of STATUS is 1.

•

If CHMED is equal to the drug, it means the drug is switched to another drug; in
other words, it is not censored.

•

Due to a lack of information, we set the start date equal to the beginning of the
year 2006 and the end date to the end of the year 2006 if such information is
unknown.

•

We also define the value of STATUS as 0 when the survival time DAYS is equal
to 364.

•

We suppose the frequency of prescription for the year 2005 is at most 12.
The SAS code [26] is shown below.
DATA SASUSER.T06; SET SASUSER.MERGEDATA06;
ARRAY MEDS(3)

MED_l - MED_3; ARRAY DATES(3) DATE 1 -

DATE_3;

DO J=l TO 3; IF DATES(J)=. THEN DATE='31DEC2006'D; END;
DO 1=1 TO 3;
IF 1=1 THEN TEMP=MEDS(I);
IF MEDS(I) NE TEMP THEN DO;
MED_NUM=I; DATE_NUM=DATES(I);

CHMED=MEDS(I);

STATUS=I; 1=3;
END;
END;
/*Define 0-1 indicators and status*/
IF CHMED='

, THEN STATUS=I;
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IF CHMED= , GLYBURIDE , THEN GLYBURIDE=O AND STATUS=l ; ELSE
GLYBURIDE=l ; ...
/*Define the variables days*/
IF DAT E lA= . THEN SDATE=DATE_l ; ELS E SDATE= ' OlJAN2006 ' D;
I F DATE 2A=. THEN EDATE=DATE_2 ; ELSE EDATE= ' 31DEC2006 ' D;
FORMAT SDATE EDATE DATE9 ; DAYS=DATDIF
(SDATE,EDATE, ' ACT/ACT ');
IF DAYS=364 THEN STATUS=O; RUN ;

Finally, we sort the new data by CHMED to get the data shown in Figure 7.14.

7
8
9
10

O1JAN2Cffi
O1JAN2Cffi
270EC2Cffi
O1JAN2Cffi
2O.IAN21X6
01JAN2006

1
1
1
1:

OlFEB2OOl
3lWJG2OIll
O1JAN2!ll

31DEC2Ol
270EC2Oll
31DEC21lli
310EC2006
310EC2006
31DEC2006
310EC2006
31DEC2006

3&1
3&1
3&1
345
3&1
333

123
3&1

Figure 7.14. Survival Data for 2006

In 2005, in order to get an accurate conclusion, we filter out the beneficiaries in
the office-based visits file rather than in the prescription drug file. We first sort out the
enrollees whose Medicare payments are greater than 0 according to the ICD 9 diagnosis
codes. Then we get the results shown in Figure 7.15; and we use the same method to get
another data set about diabetes patients in the outpatient visit file.

129

OBICD1X

DUPERSID
1

2
3

.5
6

7
8
9
10

30078019
30121012
30180024
30192012
30201026
30206025
30363015
30392041
30450010
3049401... 3

250
401
250
. ,.
250
-250
250
401
250
590
401

"

...................

OBICDJ)(

OBICD2X

-1
; 185
-1
···+-1 .....

-1
250
-1
-1
-1
401
250
-1
429
250

-1
-1
272
-1
250
716

............. ........
"

OBICD4X

-1
530
-1
-1
-1
-1
716
-1
-1
530" . ........ .........
-

,.-. ............
.................

............... ...

Figure 7.15. Diabetes Patients in Office-based Visit

Finally, we use the SQL horizontal join to get all the diabetes beneficiaries and
we use these patient IDs to find all Medicare drug plan enrollees. For analysis, we use the
life table method, setting the interval at 10 days and stratifying the data by CHMED. The
SAS code and some results are shown below.

PRoe LIFETEST DATA=SASUS ER . ST06 OUTSURV=SASUS ER . GP 06
ALPHA= O. 05 METHOD=LIFE WIDTH=10;
STRATA CHMED;
TIME DAYS*S TATUS ( O); RUN ;
Table 7.5 Summary of CensoredlUncensored Values for 2005
Summary of the Number of Censored and Uncensored Values
Stratus

CHMED

Total

Failed

Censored

Percent

1

GLYBURIDE

4

4

0

0.00

2

GL YBURIDE_METF

4

0

4

100.00

3

INSULIN

8

3

5

62. 50

4

METFORMIN

90

10

80

88.89

5

PRECOSE

3

1

2

66.67

6

ROSIGLIT AZONE

I

0

I

100.00

7

TOLAZAMIDE

2

0

2

100.00

112

18

94

83 .93

Total
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Table 7.6 Summary of CensoredlUncensored Values for 2006
Summary of the Number of Censored and Uncensored Values
CHMED

Total

Failed

Censored

Percent

1

GLYBURIDE

2

0

2

100.00

2

INSULIN

7

0

7

100.00

3

METFORMIN

100

17

83

Stratu

------------

83.00
----- - -

4

PIOGLIT AZONE

2

2

0

0.00

5

PRANDIN

I

I

0

0.00

6

PRECOSE

5

2

3

60.00

7

STARLIX

3

I

2

66.67

120

23

97

80.83

Total

Results in Tables 7.5 and 7.6 show that the medications are divided into 7 groups
in each year by CHMED. In 2005, since the number of prescriptions of rosiglitazone is
one, we do not include it. The censored percentages of glyburide- metformin and
tolazamide are 100 %, which means that it is hard for the patients to change such
medicines once they begin taking them. In 2006, we also discard prandin due to one-time
use. The censored rates of glyburide and insulin are 100 %, and the rate of metformin use
is 83 %; all of these outcomes demonstrate that the three drugs can seldom be replaced by
other medicines. In summary, the metformin and insulin uses are stable in both years.
Glyburide itself is unstable in 2005, but stable in 2006. Moreover, the average censored
rate in 2005 is a little higher than that in 2006, indicating that the usage of prescribed
drugs is more stable in 2005.
Next, we estimate the differences of survival cases among various drugs by
survival functions. The survival distribution function (SDF) in 2005 (displayed in Figure
7.16) demonstrates that none of the drug, tolazamide, is switched to the other medicines
throughout the whole year. The survival rate of metformin decreases little by little from

131

th
th
th
th
100 % to 89 % at the end of the year. Ouring the three periods, 30 - 40 , 120 - 130
and 280th - 290th days, the prescriptions of insulin largely decrease, but in the other time
periods, they remain unchanged. The sharp decrease of precose use appears between the

190th day and the 200th day, but before and after that period, the usage is stable. A large
number of beneficiaries switch their drugs from glyburide to the other medicines during

th
the following periods, the 40th day - 50 th day, the 90th - 100th day and 110 - 120th day,
which means that the survival rate of the drug decreases to 20 percent at the end of the
year. Therefore, the glyburide usage is very unstable in 2005. The SOF in 2006 (shown in
Figure 7.17) shows that insulin and metformin survive longer than the other drugs since
the survival rates are higher than that of any other drug throughout the year. None of
prescriptions of insulin are changed to another medicine until the end of the year. Only
less than 14 % of the prescriptions of metformin are switched to other drugs. Between the

90th day and the 11 Oth day, large quantities of prescriptions of pioglitazone are changed to
other drugs; however, after that, no more changes happen. The survival rate of precose

th
th
goes down to 80 % around the 220 day, to 60 percent around the 280 day and then
remains unchanged until the end of the year. The survival rate of starlix sharply decreases
on the 320th day and then stabilizes. In general, metformin and insulin uses are more
stable than those of the other medicines.
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Figure 7.16. Survival Di stribution Function for the Year 2005
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7.3 Effects of Drug Plan on the Cost Effectiveness of Medications and Health
Outcomes
The purpose of this section is to estimate the cost effectiveness of diabetes
medications and the health outcomes in Medicare in 2005 and 2006 to examine the
impact of Medicare, Part 0 using the data sets from MEPS [191.

7.3.1 Cost Effectiveness Analysis
First, we need to discover our research subjects who are Medicare drug plan
enrollees in 2006 and also joined Medicare in 2005. To keep consistency, we do not
consider the Medicare beneficiaries of age 65 in 2006; we also do not consider the
patients who switch their drugs from the year 2005 to the year 2006. We use SAS SQL
conditional selection to sort out the patients with diabetes according to the ICD9
condition code. Then we use an SQL inner join to combine the full year consolidated data
file and prescription drug file by the 10 variable, DUPERSID. After we find out the
beneficiaries who joined in Medicare, Part 0, we use the DUPERSID to match the
patients in 2005. Then we get a dataset that we need. After importing a life table, we can
combine it with the newly-generated data and calculate ICERI displayed in Figure 7.18
with the code shown below.
/*Combine the life table and 2006 Medicare part 0
beneficiary table */
PROC SQL;
CREATE TABLE SASUSER.LE06 AS
SELECT *
FROM SASUSER.LIFETABLEI AS LT,
SASUSER.BCHWLQ06 AS BC
WHERE LT.AGE=BC.AGE06X; QUIT;
/*Calculate the 2006 QALY for different genders*/
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DATA SASUS ER . QALY06 ; SET SASUSER . LE06 ;
IF SEX=l THE N QALY06=MALE*LQ06;
I F SEX=2 THEN QALY06=FEMALE*LQ06i RUN;
PROC SORT DATA=SASUS ER . QALY06 ; BY DUPE RSID ; RUN ;
/*To calculate t h e ICER */
PROC SQL ; CREAT E TABL E SASUS ER . CICER AS
SELECT DUP ERSID ,

SRXNAME,

((TOTMCR06 - TOTMCROS) /
FROM SASUS ER . IC ER ;

2
3
4

5
6
7
8
9
10

30136026
30180024
30363015
30386013
30392041
30437028
30489011
30507010
30516018

QALY05 ,

QALY0 6 ,

TOTMCR05 , TOTMCR06 ,

(QALY06-QALYOS)) AS ICERl

QUIT ;

GliPIZIDE
GLYBURIDE
GliPIZIDE
GliPIZIDE
GLYBURIDE
GLY8URIDE
STARLIX
GLYBURIDE_M .
GLYBURIDE

6.8
4.42
3.956
8.934
2.71
1.336
11 .024
5.788
7.888

9.768
4.184
3.736
11376
5.164
4.008
7.86
5.51 2
7.576

0
6974
710
0
2120
224
0
149
179

11084
1947
4578
1782
6140
2434
·i
3952
783
2737

leER1
·330223.68
3734.50135
21300.8475
·1 7581.818
729.72973
1638.141 81
827.095808
·1249.0518
·2297.1014
·8198.7179

Figure 7.18. leER Table

Table 7.7 leER by Different Diabetes Drugs
SRXNAME

Mean

N

GLIMEPIRIDE

-1268.78

4

GLIPIZIDE

-12573.77

49

GLYBURIDE

-4728 .05

45

GL YBURIDE_METFORMIN

1934.47

10

INSULIN

-14203.62

16

METFORMIN

896.1215818

44

STARLIX

-590.0887749

3

Once we get the table, we use the proc means procedure in base SAS to get the
average leER value for each drug shown in Table 7.7. Here, a negative leER means that
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there are savings for the year 2006 over the year 2005. For example, the comparison
between the year 2006 and the year 2005 for insulin treatment shows a cost saving of
$14,203.62 in 2006. For a positive ICER, the bigger the ICER, the less efficient the new
method. Therefore, Table7.7 demonstrates that insulin becomes the most cost-effective in
2006, while Glyburide-metformin is the most inefficient treatment, and metformin is a
close second.

7.3.2 Medical Resources Utilization
Next, we evaluate utilizations of healthcare resources by comparing the
frequencies of office-based visits, outpatient visits and times of prescription drugs filled
as well as the length of stay in the hospital or home health providers separately. We
firstly find the data containing the times of office-based visits in these two years, then we
use the times of visits in 2005 as the denominator; the difference of the times in these two
years is used as numerator to calculate the increasing or decreasing rate. Finally, we get
the average rates for each drug. In the same way, we also get the increasing and
decreasing rates in the other cases.
Table 7.8 shows that compared to the year 2005, the Medicare diabetes patients
receive more drug treatments in 2006 since the drug refill rates increase by an amount
varying from 17% to 66%. At the same time, the average LOS (length of stay) in the
hospital of the insulin or glipizide users is largely decreased by 80% or 61 %, which
means that adequate insulin or glipizide usage saves considerable hospitalization
resources. However, the average of the prescription frequency and LOS of metformin
users increases by 73% and 200 % respectively from the year 2005 to the year 2006. It is
also true for glyburide users. In other words, the drug plan makes these two drug
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treatments more inefficient. The relationship between the LOS in the hospital and the
home health provider for most drug users is negative; the longer the stay using home
health providers, the shorter the stay in the hospital. Considering the costs of
hospitalization are higher than those of home health providers, the patients should
sufficiently utilize the home health agency services.

Table 7.8 Ratios in Utilizations of Healthcare Resources
SRXNAME

OBTRATIO

OPTRATIO

GLIMEPIRIDE

0.03

0

0.66

0.52

0.19

0.22

GLIPIZIDE

RXTRATIO LOS RATIO

-0.61

--

0.50
-----------

GLYBURIDE

1.30

0.82

0.33

GLYBURIDE

-0.12

0.80

0.20

- METFORMIN
INSULIN

HHDRATO

METFORMIN

0.54

STARLIX

0.61

-0.01
-\.0

I

-------r--

-- --

0.01

0.65

-0.29

0.17

0.29

0.73

i

i

-------

-0.8

-0.07

2.0

-0.40

0.45

7.3.3 Health Status
Finally, we use the decision tree model to investigate which factors have vital
effects on the beneficiaries' health status. We input all the variables, frequencies of
physician visits, drug prescriptions, Al C tests, ER (Emergency Room), LOS in the
hospital or home healthcare agency, gender, age and family size. We set the health status
as a predicted target. Figure7 .19 demonstrates that in 2005, the frequency of Al C tests
and the physician visits have vital effects on a patients' health. Figure 7.20 indicates that
in 2006, the frequency of drugs filled becomes a key factor to the patient's health
status. However, there is something in common between these two years. LOS in the
hospital and family size are not important factors to health conditions.
137

I4 5

<

>=

1

I

>=

I6.5

>=

45

I 25

<

I

I
Average
H:

Des. llMESTESTED F...

I4.5

-<

>= 145

I95.5

I

J..vtraqe

0.:1

Avenge

5

N:

6

N:

R:

<

158

>=

I

Figure 7.19. Decision Tree for 2005 Health Status

•

.,u.~

<

I0.5

R:

>=

I

1

0.5

I
AVI!I.Ago!
H:

0 . 45

:5

>=
Aftt~

.:

,

0.53
75

AGE AS OF 12/3 1/06

I

C.

>=

.:

AverAge

I84.5
I

AVetAge
N:

~5 5

I
>= 58
L 0. 48
lvuege

0.3 3
6

Figure 7.20. Decision Tree for 2006 Health Status

138

I

0. 3:::
:2

I25

7.4 Conclusion
Based on the analyses in Section 7.2, we can draw the conclusion that Medicare,
part D indeed greatly increases the expenditures of Medicare on diabetes medications.
The prescription drug plan itself reduces the choices of the medicines for diabetes for
each year. We also discover that generally, the usage of insulin and metformin is always
more stable than that of other drugs. However, glyburide usage is very unstable in 2005
but stable in 2006. In addition, more drugs are switched into other medicines in 2006,
which indicates that the use of drugs is less stable than that in 2005. It is also discovered
that in 2005, female patients spend more on insulin and supplies, while the males spend
more on metformin. In 2006, the female beneficiaries pay more for metformin.
Cost-effectiveness analysis suggests that Medicare, Part D makes the insulin
treatment the most efficient, while the combination of glyburide - metformin is the least
effective. Our results also demonstrate that under this drug plan, the Medicare
beneficiaries can receive more sufficient drug treatments than ever before. In the
meanwhile, enough usage of some drugs such as insulin can decrease the usage of
hospital resources. In contrast, the metformin users stay in the hospital for a longer time
in 2006. Another discovery is that using the drugs properly can improve the patient health
status.
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CHAPTER VIII
CONCLUSION

In this dissertation, we introduced pattern recognition analysis and supervised!
unsupervised machine learning algorithms as well various kinds of linear statistical
models into the study of diabetes patients in the Medicare population and we proposed
several methods to decrease Medicare expenditures while improving healthcare quality.
First, we utilized the linear statistical models to complete a cost analysis of
diabetes outpatients in Medicare. We conclude that most predictors that we find are key
factors influencing the costs and we suggest that outpatients with diabetes should often
monitor their blood glucose level and the patients with such complications as anemia and
heart diseases need more medical care. By these means, the costs can be decreased to
some extent.
Second, we applied supervised learning approaches such as the decision tree
model and market basket analysis to an outcomes study of inpatients. We arrive at the
conclusions that the patients who have procedures related to heart diseases often need
other procedures; neither age nor the end-stage renal disease is the key factor to mortality,
which is contrary to widely held belief.
Third, we employed pattern recognition analysis and the decision tree model in
readmission risk analysis. Patients with cardiovascular or kidney co-morbidities have a
higher risk of readmission than those with other diseases. Another discovery is that the
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patients without professional medical services are more likely to be readmitted to the
hospitals after discharge.
Fourth, we performed two- way interaction effects analysis using the generalized
linear model with a gamma distribution, the logistic regression model and the Poisson
regression model. We find that as for inpatients expenditures, most two -way interaction
effects between diabetes complications are significant; when the response variable is
frequency of hospitalization, only the effects between kidney disease and the other
diseases are significant to the Poisson regression model. We also conclude that the
patients who have both heart disease and kidney disease have a much higher risk of dying
since the interaction effect between these two diseases are significant to mortality in the
logistic regression model.
Fifth, we used survival analysis to analyze diabetes drug usage. Results
demonstrate that insulin and metformin are more stable than other drugs in terms of usage
and the uses of drugs in 2005 are more stable than those in 2006 with the influence of
Medicare, Part D.
Finally, we applied cost-effectiveness analysis to diabetes medications. The
results indicate that with the introduction of the Medicare drug plan, insulin becomes the
most cost-effective treatment and the combination of glyburide and metformin is the most
inefficient. They also demonstrate that metformin users highly increase their length of
hospitalization and the frequency of prescriptions from the year 2005 to the year 2006.
In summary, in this dissertation, several new algorithms and methods are
introduced or improved and some suggestions are proposed to decrease Medicare costs
and improve health outcomes.
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